var title_f6_61_7120="Distribution of AFP with NTDs";
var content_f6_61_7120=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Distribution of maternal serum alpha-fetoprotein (AFP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 350px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    AFP levels (corrected for maternal weight) in pregnancies with open spina bifida and pregnancies without neutral tube defects (unaffected) at 16 weeks of gestation with gestational age estimated by dates (from first day of last menstrual period, LMP) and by an ultrasound imaging (fetal biparietal diameter measurement, BPD). MoM, multiple of the median for unaffected pregnancies of the same gestation age.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data adapted from: Ward, N, Kennard, A. Prenatal Screening for Neutral Tube Defects and Down Syndrome. In: Principles and Practice of Medical Genetics, 3rd ed, Rimoin, DC (Ed), Churchill Livington Inc, New York 1997. p. 548.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_61_7120=[""].join("\n");
var outline_f6_61_7120=null;
var title_f6_61_7121="Miltefosine: International drug information";
var content_f6_61_7121=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Miltefosine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Impavido (BD, BR, CO, DE, IN);",
"     </li>",
"     <li>",
"      Miltex (AT, BE, BG, BR, CL, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IL, IT, LT, LV, MY, SE, SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F3466627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiparasitic Agent, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F3466628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cutaneous metastases of breast cancer; treatment of visceral leishmaniasis",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F3466630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Visceral leishmaniasis (black fever): 2.5 mg/kg/day for 28 days (maximum dose: 150 mg/day)",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3466631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: 10 mg, 50 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10496 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-EFEE8658EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_61_7121=[""].join("\n");
var outline_f6_61_7121=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302637\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466627\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466628\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466630\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821093\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466631\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10496\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10496|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_61_7122="Subacute cutaneous lupus - papular";
var content_f6_61_7122=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subacute cutaneous lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous, scaly papules are present on the upper back.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_61_7122=[""].join("\n");
var outline_f6_61_7122=null;
var title_f6_61_7123="Evaluation of anemia in children";
var content_f6_61_7123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 602px\">",
"   <div class=\"ttl\">",
"    Evaluation of anemia in children according to mean corpuscular volume",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 582px; height: 678px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MCV: mean corpuscular volume; Retic: reticulocyte count; WBC: white blood cell count; PLT: platelet count; G-6-PD: glucose 6-phosphate dehydrogenase;",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Nathan DG, Oski FA. Hematology of Infancy and Childhood, 4th ed, WB Saunders, Philadelphia, PA 1993. p. 352.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_61_7123=[""].join("\n");
var outline_f6_61_7123=null;
var title_f6_61_7124="Cysteamine: Pediatric drug information";
var content_f6_61_7124=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cysteamine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15510916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cystagon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F15513219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticystine Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Urinary Tract Product",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F15513226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose-related side effects resulting in withdrawal from research studies occurred more frequently in those patients receiving 1.95 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day as compared to 1.3 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day; start at the lowest dose and titrate gradually to prevent intolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Initiate therapy with",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      6",
"     </sub>",
"     of maintenance dose and titrate slowly over 4-6 weeks:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;12 years: Initial: 1.3 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 4 divided doses; may increase gradually to a maximum of 1.95 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years (&gt;110 lbs) and Adults (&gt;110 lbs): 2 g/day in 4 divided doses; dosage may be increased gradually to 1.95 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Approximate Cysteamine Initial Dose:",
"      <b>",
"       (to achieve &sim;1.3 g/m",
"       <sup>",
"        2",
"       </sup>",
"       /day)",
"      </b>",
"     </caption>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Weight",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (lbs)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg every 6 h)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &le;10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11-20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         150",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         21-30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         31-40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         41-50",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         300",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         51-70",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         350",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         71-90",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         400",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         91-110",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         450",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;110",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F15510970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cystagon&reg;: 50 mg, 150 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F15510918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15513227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Contents of capsule may be sprinkled over food; if a dose is missed, take it as soon as possible then return to normal dosing schedule; if identified within 2 hours of next scheduled dose, skip dose; do",
"     <b>",
"      not",
"     </b>",
"     double the next dose",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F15513223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15513220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of nephropathic cystinosis",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F15510933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal thinking, ataxia, confusion, depression, dizziness, emotional lability, encephalopathy, fever, hallucinations, headache, impaired cognition, jitteriness, lethargy, nervousness, nightmares, seizure, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, duodenal ulceration, duodenitis, dyspepsia, gastroenteritis, gastrointestinal bleeding, gastrointestinal ulcers, halitosis, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Abnormal LFTs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hyperkinesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Compression fracture, genu valgum, hyperthermia, interstitial nephritis, intracranial hypertension (benign), joint hyperextension, leg pain, molluscoid pseudotumor, osteopenia, papilledema, pseudotumor cerebri, renal failure, scoliosis, skin fragility, skin lesion, skin striae",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15513221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cysteamine, penicillamine, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F15513234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with a history of gastric or duodenal ulcer; gastrointestinal ulcers and bleeding have been reported; promptly evaluate if signs and symptoms occur; adjust dose downward if severe GI symptoms develop (most common during initiation of therapy). Use with caution in patients with a history of blood dyscrasias.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15513222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Leukocyte cystine levels should be monitored during oral cysteamine therapy (at least every 3 months); cysteamine should be given in the lowest dose possible to achieve adequate leukocyte cystine depletion; toxicity may be reduced by initiating therapy with a slowly increasing dose schedule; if skin rash develops, discontinue treatment until rash clears; may then resume treatment at a lower dose with a slow titration to the therapeutic dose; if severe rash develops (eg, erythema multiforme bullosa or toxic epidermal necrolysis), immediately discontinue and do not resume therapy. High doses of cysteamine salts have been associated with purplish hemorrhagic lesions over the elbow area on both arms and have been described as molluscoid pseudotumors. Skin striae, bone lesions (described as osteopenia, compression fractures, scoliosis, and genu valgum) along with leg pain and joint hyperextension may also be present. Reduce dosage if this reaction occurs. Routine monitoring of skin and bones is recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     CNS symptoms such as seizures, lethargy, somnolence, depression, and encephalopathy have been associated with cysteamine therapy; patients who develop these symptoms should be carefully evaluated and the dosage adjusted as necessary; use with caution in patients with neurological disorder. Benign intracranial hypertension (or pseudotumor cerebri) and/or papilledema with cysteamine therapy has resolved with diuretic therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15510936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15510937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15510924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15510925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use only when the potential benefits outweigh the potential hazards to the fetus; in animal studies, cysteamine is teratogenic and fetotoxic. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15513228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood counts and liver enzymes during therapy; blood pressure; monitor leukocyte cystine measurements to determine adequate dosage and compliance (measure 5-6 hours after administration); monitor skin and bone",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F15513229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Leukocyte cystine level goal (measured 5-6 hours after cysteamine dose): &lt;1 nmol of half-cystine/mg protein (some measurable benefits have been seen with levels &lt;2); routine measurements are recommended every 3 months",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15513224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reacts with cystine in the lysosome to convert it to cysteine and to a cysteine-cysteamine mixed disulfide, both of which can then exit the lysosome in patients with cystinosis, an inherited defect of cystine transport. Patients with untreated cystinosis develop renal tubular Fanconi syndrome leading to progressive glomerular failure and end-stage renal failure in addition to growth failure, rickets, and photophobia due to cystine deposits in the cornea.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F15513235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Peak effect: 1.8 hours",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Duration: 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15513225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Children: 156 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Mean: 52%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 1.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Clearance: Children: 1.2 L/minute",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F15513236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness or impair ability to perform activities requiring mental alertness or physical coordination; notify healthcare provider if skin rash, changes to skin, stomach pain, nausea, vomiting, loss of appetite, severe headache, or a change in vision occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87034 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-F7325097AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_61_7124=[""].join("\n");
var outline_f6_61_7124=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510916\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513219\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513226\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510970\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510918\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513227\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513223\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513220\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510933\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513221\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513234\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513222\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510936\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510937\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510924\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15510925\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513228\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513229\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513224\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513235\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513225\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513236\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/87034\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/87034|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43122?source=related_link\">",
"      Cysteamine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/40/8836?source=related_link\">",
"      Cysteamine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/56/12164?source=related_link\">",
"      Cysteamine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/49/16148?source=related_link\">",
"      Cysteamine (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_61_7125="Bumble bee";
var content_f6_61_7125=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F73585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F73585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bumble bee",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_61_7125=[""].join("\n");
var outline_f6_61_7125=null;
var title_f6_61_7126="Digital subcutaneous abscess";
var content_f6_61_7126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Digital subcutaneous abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 583px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A subcutaneous abscess of the finger presents with localized swelling, erythema, and restricted motion at the adjacent joints. The digit is usually in a flexed posture and there may be evidence of an inflamed puncture wound from a penetrating injury. In late presentations, the abscess may be pointing or discharging through a sinus.",
"    <br>",
"     (A) Palmar digital subcutaneous abscess.",
"     <br>",
"      (B) Dorsal digital subcutaneous abscess.",
"      <br>",
"       (C) Lateral digital subcutaneous abscess.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_61_7126=[""].join("\n");
var outline_f6_61_7126=null;
var title_f6_61_7127="Priapism";
var content_f6_61_7127=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Priapism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/61/7127/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/61/7127/contributors\">",
"     Serkan Deveci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/61/7127/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/61/7127/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/61/7127/contributors\">",
"     Robert S Hockberger, MD, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/61/7127/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/61/7127/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/61/7127/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"priapism\" is derived from Priapus, the Greek god of fertility, gardening, and lust who is depicted with a massive phallus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/1\">",
"     1",
"    </a>",
"    ]. Priapus, the illegitimate son of Zeus and Aphrodite, was cursed by Zeus' wife Hera upon learning of Aphrodite's pregnancy. The boy Priapus was born with oversized genitalia and subsequently rejected by Aphrodite. He was raised by shepherds, who noticed that flowers would bloom and animals would copulate in his vicinity.",
"   </p>",
"   <p>",
"    Priapism is defined as a persistent erection of the penis or clitoris that is not associated with sexual stimulation or desire. The focus of this topic will be penile priapism. Studies differ on the length of time of erection used to define priapism, but most studies identify priapism as an erection lasting at least four hours.",
"   </p>",
"   <p>",
"    Priapism is relatively uncommon, but can occur in all age groups and is particularly common in those with sickle cell disease.",
"   </p>",
"   <p>",
"    Priapism is generally classified as ischemic or nonischemic. Ischemic priapism is a urologic emergency, whereas nonischemic priapism is usually self-limited.",
"   </p>",
"   <p>",
"    Issues related to epidemiology, pathophysiology, diagnosis, and management of priapism will be reviewed here. Particular issues related to priapism in sickle cell disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23017?source=see_link\">",
"     \"Diagnosis and management of priapism in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of priapism in men is 1.5 cases per 100,000 person-years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/2\">",
"     2",
"    </a>",
"    ]. Clitoral priapism occurs even less commonly [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Priapism can occur in any age group. However, there is a bimodal peak distribution of incidence, occurring between 5 and 10 years in children and 20 to 50 years in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penile erection begins with the relaxation of the smooth muscle of cavernosal arteries and tissue, leading to increased nonischemic inflow and decreased venous outflow (",
"    <a class=\"graphic graphic_figure graphicRef66964 \" href=\"UTD.htm?11/3/11319\">",
"     figure 1",
"    </a>",
"    ). As intracorporal pressure rises to mean arterial pressure, the inflow of blood ceases. Priapism generally involves the corpora cavernosa only, although occasionally affects the corpus spongiosum and the glans penis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The underlying cause of priapism is usually not known, but priapism has been associated with several medications and disease states (",
"    <a class=\"graphic graphic_table graphicRef54354 \" href=\"UTD.htm?13/1/13339\">",
"     table 1",
"    </a>",
"    ). The most common known cause among adults is medication use, especially with intracavernosal injections, accounting for 25 percent of adult cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/6\">",
"     6",
"    </a>",
"    ]. The most common associated diagnosis in children is sickle cell disease.",
"   </p>",
"   <p>",
"    There are two main types of priapism: ischemic and nonischemic priapism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ischemic priapism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic priapism (also known as low flow, anoxic, or veno-occlusive priapism) is the most common form of priapism.",
"   </p>",
"   <p>",
"    Ischemic priapism is prolonged erection with failure of detumescence due to impaired relaxation and paralysis of cavernosal smooth muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. This results in a compartment syndrome, with increasing hypoxia and acidosis in the cavernous tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nitric oxide has been proposed as an important mediator in the development of priapism. Nitric oxide serves a fundamental role in the erectile response by mediating relaxation of smooth muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/11\">",
"     11",
"    </a>",
"    ]. Understanding of the nitric oxide pathway led to the development and widespread use of phosphodiesterase type 5 (PDE5) inhibitors in the treatment of erectile dysfunction. PDE5 inhibitors inhibit breakdown of cGMP and potentiate nitric oxide-mediated penile smooth muscle relaxation for erectile function. A regulatory defect in the nitric oxide pathway has been proposed to account for some patients with priapism, particularly those with sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23017?source=see_link\">",
"     \"Diagnosis and management of priapism in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prolonged erection in ischemic priapism leads to structural damage of erectile tissue, due in part to tissue edema [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Tissue damage is believed to occur at the microscopic level as early as four to six hours after onset of erection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/10,15\">",
"     10,15",
"    </a>",
"    ]. Significant structural changes in the cavernous smooth muscle can be seen after 12 hours duration of priapism [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/15\">",
"     15",
"    </a>",
"    ]. Irreversible damage can be identified after 24 to 48 hours of priapism, including necrosis of cavernosal smooth muscle and endothelial cells, fibroblast proliferation, and ultimately fibrosis of corpus cavernosa.",
"   </p>",
"   <p>",
"    The duration of priapism is strongly associated with incidence of subsequent erectile dysfunction. Ninety percent of men with an ischemic priapism lasting 24 hours do not regain the ability to have sexual intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/16\">",
"     16",
"    </a>",
"    ]. Early relief of priapism with return of normal flaccidity is not likely to be associated with long term sequelae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Recurrent priapism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent priapism (also known as stuttering priapism) is an uncommon condition usually occurring in men with sickle cell anemia. Recurrent priapism is a form of ischemic priapism, which starts off with erections of short duration. The onset is usually during sleep with persistence upon waking. These episodes become longer in duration and more frequent, eventually leading to a full-blown ischemic priapism event. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23017?source=see_link\">",
"     \"Diagnosis and management of priapism in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathophysiology of this type of priapism is not fully elucidated. A mechanism based on dysregulation of nitric oxide and phosphodiesterase type 5 in the corporal smooth muscle has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/12,17-20\">",
"     12,17-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nonischemic (high flow) priapism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonischemic priapism (also known as high flow, arterial, or congenital priapism) occurs less commonly than ischemic priapism and is usually the result of a fistula between the cavernosal artery and corpus cavernosum.",
"   </p>",
"   <p>",
"    Nonischemic priapism is commonly related to penile or perineal trauma, often from needle injury of the cavernosal artery. Blunt trauma, as can occur from bicycling, may also damage the cavernosal artery, leading to increased flow through the corpora cavernosa [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/21\">",
"     21",
"    </a>",
"    ]. The onset of post-traumatic, nonischemic priapism can occur up to 72 hours after injury.",
"   </p>",
"   <p>",
"    Congenital arterial malformations may also be a cause of nonischemic priapism.",
"   </p>",
"   <p>",
"    Nonischemic priapism does not represent an emergency situation, as the cavernous blood is well-oxygenated. Nonischemic priapism will resolve spontaneously in up to 62 percent of untreated cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of priapism is generally straightforward. Visual inspection reveals an erect penis, and the erection has been present for more than two to four hours in the absence of sexual excitation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/6\">",
"     6",
"    </a>",
"    ]. Duration of erection may be shorter for patients with recurrent priapism. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Recurrent priapism'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnosis of the type of priapism may be determined by a detailed history and physical examination. In addition, cavernous blood gas analysis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Doppler ultrasonography can immediately distinguish between ischemic and nonischemic priapism. Diagnosing the type of priapism is particularly important since delayed diagnosis of ischemic priapism can lead to irreversible damage of the penile tissue and erectile dysfunction. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following information should be obtained when taking an initial history:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duration of erection",
"     </li>",
"     <li>",
"      Prior episodes",
"     </li>",
"     <li>",
"      Medications",
"     </li>",
"     <li>",
"      Use of recreational drugs",
"     </li>",
"     <li>",
"      History of hematological disease, especially sickle cell anemia",
"     </li>",
"     <li>",
"      Penile or perineal trauma",
"     </li>",
"     <li>",
"      Presence and severity of pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In ischemic priapism, the patient typically presents with a painful and rigid erection. A history of sickle cell disease or other hematologic abnormality also suggests ischemic priapism. In rare cases, ischemic priapism can present with penile gangrene, usually resulting in necrosis of the entire penis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonischemic priapism is associated with a history of trauma (often related to needle injection or urologic procedures) and an erection that is less painful and usually less than fully rigid.",
"   </p>",
"   <p>",
"    Genitalia, the perineum, and the abdomen should be carefully examined for penile rigidity and signs of trauma or malignancy. With priapism, examination of the penis reveals engorged corpora cavernosa, but in contrast to normal erections, the corpus spongiosum and glans penis can remain flaccid.",
"   </p>",
"   <p>",
"    Determining whether priapism is ischemic or nonischemic may be possible after history and physical examination alone, though in most patients additional studies are helpful. Cavernosal blood gas analysis is the most useful means for distinguishing the type of priapism and should be performed when the diagnosis is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cavernosal blood gas analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood should be aspirated from the corpora cavernosum for a blood gas analysis if erection persists for greater than four hours to differentiate between ischemic and nonischemic forms. A small caliber needle can be used (ie, 19 to 21 gauge) for easier control and to minimize trauma. Blood is aspirated from one side of the corpus cavernosum, and 3 to 5 mL is typically withdrawn.",
"   </p>",
"   <p>",
"    The color of the aspirated blood sample is black in patients with ischemic priapism. Corporal blood gas analysis will show hypoxemia, hypercarbia, and acidemia. In contrast, the color of aspirated blood is red in patients with nonischemic priapism. Blood gas analysis will show normal levels of oxygen, carbon dioxide, and pH (",
"    <a class=\"graphic graphic_table graphicRef51913 \" href=\"UTD.htm?1/35/1595\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other blood studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood tests to evaluate for possible hemoglobinopathies or other blood dyscrasias should also be performed. A complete blood count may reveal anemia, leukemia, or platelet abnormalities. Reticulocyte count and hemoglobin electrophoresis are indicated when sickle cell disease, thalassemia major, or leukemia is suspected. A hemoglobin analysis will not yield immediate results, but a peripheral smear may identify sickled red cells or Howell-Jolly bodies, reflecting hyposplenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=see_link\">",
"     \"Diagnosis of sickle cell syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Toxicology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urine toxicology and psychoactive drug testing may be performed if drug use is known or suspected (",
"    <a class=\"graphic graphic_table graphicRef54354 \" href=\"UTD.htm?13/1/13339\">",
"     table 1",
"    </a>",
"    ). Usual doses of several classes of psychoactive drugs, including antidepressants, may cause priapism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Doppler ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler ultrasonography may be performed as an alternative to cavernosal blood gas to differentiate between ischemic and nonischemic types of priapism. Minimal or absent blood flow with Doppler ultrasonography is observed in the cavernosal arteries in ischemic priapism, whereas normal to high blood flow is observed in nonischemic priapism [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/24\">",
"     24",
"    </a>",
"    ]. Doppler ultrasound can also detect cavernous arterial fistula, pseudoaneurysm, or other anatomic abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative safety and efficacy of different treatments for priapism are not well established. Most of the current evidence is derived from case reports or case series as there are no randomized controlled trials and a paucity of evidence-based guidelines. A management algorithm for priapism has been developed by the American Urological Association, and is shown with modifications in a figure (",
"    <a class=\"graphic graphic_algorithm graphicRef75061 \" href=\"UTD.htm?43/25/44446\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment of ischemic priapism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic priapism is an urgent condition that requires rapid detumescence to avoid long-term sequelae.",
"   </p>",
"   <p>",
"    Oral analgesics should be given to control the pain, and opioids should be prescribed if the pain is severe. Urgent urologic consultation is indicated, when possible to arrange.",
"   </p>",
"   <p>",
"    In our practice, we do treat patients with ischemic priapism of less than four hours duration with an intracavernosal injection of a sympathomimetic drug (eg, for a procedurally induced erection, which is commonly seen in the urologic office setting). After four hours duration, aspiration (with or without irrigation) combined with intracavernosal injection of a sympathomimetic drug is considered to be the optimal treatment.",
"   </p>",
"   <p>",
"    Sympathomimetics induce contraction of the cavernous smooth muscle and thus permit venous outflow. In one review, resolution of priapism was reported in 24 to 36 percent in studies treating patients with aspiration alone with or without irrigation, and in 43 to 81 percent in studies treating with intracavernosal sympathomimetic medication with or without irrigation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/22\">",
"     22",
"    </a>",
"    ]. The risk of post-priapism erectile dysfunction was also lower with sympathomimetic use. Aspiration with intracavernosal alpha agonist injection was considered the treatment of choice for ischemic priapism by an international committee on priapism [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     Phenylephrine",
"    </a>",
"    , a pure alpha-adrenergic agonist, is considered the sympathomimetic of choice for ischemic priapism by the American Urological Association [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/22\">",
"     22",
"    </a>",
"    ]. Phenylephrine has minimal risk of cardiovascular side effects compared to other sympathomimetic medications such as epinephrine, norepinephrine, and ephedrine. Although trial data are lacking, several small observational studies demonstrate prompt resolution of priapism with phenylephrine intracavernosal injection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/25-28\">",
"     25-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The systemic side effects of sympathomimetics include alpha adrenergic-mediated hypertensive effects and beta adrenergic-mediated ionotropic and chronotropic effects. Side effects include acute hypertension, headache, and cardiac arrhythmia. Blood pressure monitoring is recommended for all patients, and cardiac monitoring is recommended for patients with a history of cardiovascular disease.",
"   </p>",
"   <p>",
"    Using a non-heparinized 19-gauge butterfly needle, approximately 5 mL of blood should be aspirated to decompress the corpora.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     Phenylephrine",
"    </a>",
"    should then be injected into one side of the corpus cavernosum. In adults, phenylephrine should be diluted with normal saline to provide a final concentration of approximately 100 mcg to 500 mcg per mL. One mL intracavernous injections of the freshly diluted phenylephrine solution are administered every three to five minutes until resolution or up&nbsp;until one hour, before deciding whether the treatment will be successful [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/22\">",
"     22",
"    </a>",
"    ]. Lower concentrations and smaller volumes&nbsp;are appropriate for use in children and those with severe cardiovascular disease. It may be necessary to repeat aspiration and phenylephrine injections over several hours to achieve detumescence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If patients do not respond to repeated cavernous aspiration and alpha agonist therapy, shunt surgery is the next treatment option. A surgical fistula is created between the corpus cavernosum and the corpus spongiosum, glans penis, or one of the penile veins. Several observational studies have shown some efficacy in relieving ischemic priapism, with limited preservation of erectile function and some patients requiring multiple surgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. Several surgical shunting procedures are available. Implantation of a penile prosthesis at the time of fistula surgery has been suggested for patients with late presentation (&ge;72 hours), because the prognosis for sexual function is poor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment of recurrent priapism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episodes of recurrent priapism should be treated as ischemic priapism events. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Treatment of ischemic priapism'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with sickle cell disease and other hematologic disorders should be treated simultaneously for their hematologic issues while also receiving treatment for ischemic priapism.",
"   </p>",
"   <p>",
"    Prevention is an important goal for patients with recurrent priapism. Preventive treatments for patients with sickle cell disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23017?source=see_link\">",
"     \"Diagnosis and management of priapism in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treatment of nonischemic (high flow) priapism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonischemic priapism is not an urgent condition and may resolve spontaneously after several hours to a few days. A management algorithm for nonischemic priapism is available (",
"    <a class=\"graphic graphic_algorithm graphicRef75061 \" href=\"UTD.htm?43/25/44446\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Once ischemic priapism has been ruled out, observation alone is appropriate for initial management of nonischemic priapism. Aspiration and injectable sympathomimetic agents have not been shown to be effective for nonischemic priapism. Sympathomimetic agents can also lead to cardiovascular side effects without notable benefit.",
"   </p>",
"   <p>",
"    Patients can be managed as outpatients. The risk of short-term complications in patients with nonischemic priapism appears to be small, and follow up with a urologist within approximately one week for further treatment is most likely safe and appropriate.",
"   </p>",
"   <p>",
"    If the patient cannot accept observation, arteriography with embolization of the fistula may be indicated. Embolization can be done using gelfoam, metallic coils, or autologous clot. Several observational studies have shown prompt relief of nonischemic priapism with preservation of erectile function [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Resolution of nonischemic priapism with arterial embolization can be as high as 89 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If initial embolization fails, repeat angiographic embolization or open surgical ligation of the ruptured artery with the aid of intraoperative ultrasonography may be necessary. Surgical ligation has, in isolated case reports, relieved nonischemic priapism after failed embolization therapy, with partial to full recovery of erectile function [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7127/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/40/34433?source=see_link\">",
"       \"Patient information: Priapism (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Priapism most commonly occurs among young adult men, with an incidence of 1.5 cases per 100,000 person years. Priapism has been associated with several medications and disease states, including sickle cell disease (",
"      <a class=\"graphic graphic_table graphicRef54354 \" href=\"UTD.htm?13/1/13339\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two main types of priapism: ischemic and nonischemic. Recurrent priapism, a subtype of ischemic priapism, is characterized by recurrent erections of short duration. Ischemic priapism usually presents with a painful, rigid erection and requires emergent therapy. Untreated, this may cause permanent erectile dysfunction. Nonischemic priapism usually presents after trauma, without a painful or rigid erection, and resolves spontaneously. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to history and physical examination, cavernous blood gas analysis can be performed to distinguish between ischemic and nonischemic priapism. Laboratory testing and Doppler ultrasound are adjunctive tests. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with ischemic priapism, we recommend intracavernosal injection with a sympathomimetic agent (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We prefer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"       phenylephrine",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      with 1mL injection) to other agents based on fewer adverse effects. In addition to sympathomimetic injection, we suggest cavernosal blood aspiration (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment of ischemic priapism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with recurrent priapism events that persist beyond four hours should be treated similarly to patients with ischemic priapism. Recurrent priapism is usually associated with sickle cell disease. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment of recurrent priapism'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23017?source=see_link\">",
"       \"Diagnosis and management of priapism in sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with nonischemic priapism, we suggest conservative management rather than a specific intervention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Nonischemic priapism can last hours to days and resolves spontaneously in the majority of patients. Patients who desire immediate treatment can be managed with arterial embolization (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment of nonischemic (high flow) priapism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346924829\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. John P. Mulhall, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/1\">",
"      Papadopoulos I, Kel&acirc;mi A. Priapus and priapism. From mythology to medicine. Urology 1988; 32:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/2\">",
"      Eland IA, van der Lei J, Stricker BH, Sturkenboom MJ. Incidence of priapism in the general population. Urology 2001; 57:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/3\">",
"      Medina CA. Clitoral priapism: a rare condition presenting as a cause of vulvar pain. Obstet Gynecol 2002; 100:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/4\">",
"      Cherian J, Rao AR, Thwaini A, et al. Medical and surgical management of priapism. Postgrad Med J 2006; 82:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/5\">",
"      Lewis JH, Javidan J, Keoleian CM, Shetty SD. Management of partial segmental priapism. Urology 2001; 57:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/6\">",
"      Burnett AL, Bivalacqua TJ. Priapism: current principles and practice. Urol Clin North Am 2007; 34:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/7\">",
"      Broderick GA, Gordon D, Hypolite J, Levin RM. Anoxia and corporal smooth muscle dysfunction: a model for ischemic priapism. J Urol 1994; 151:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/8\">",
"      Kim NN, Kim JJ, Hypolite J, et al. Altered contractility of rabbit penile corpus cavernosum smooth muscle by hypoxia. J Urol 1996; 155:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/9\">",
"      Moon DG, Lee DS, Kim JJ. Altered contractile response of penis under hypoxia with metabolic acidosis. Int J Impot Res 1999; 11:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/10\">",
"      Pryor J, Akkus E, Alter G, et al. Priapism. J Sex Med 2004; 1:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/11\">",
"      Coward RM, Carson CC. Tadalafil in the treatment of erectile dysfunction. Ther Clin Risk Manag 2008; 4:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/12\">",
"      Burnett AL. Nitric oxide in the penis--science and therapeutic implications from erectile dysfunction to priapism. J Sex Med 2006; 3:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/13\">",
"      HINMAN F Jr. Priapism; reasons for failure of therapy. J Urol 1960; 83:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/14\">",
"      BURT FB, SCHIRMER HK, SCOTT WW. A new concept in the management of priapism. J Urol 1960; 83:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/15\">",
"      Spycher MA, Hauri D. The ultrastructure of the erectile tissue in priapism. J Urol 1986; 135:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/16\">",
"      Pryor JP, Hehir M. The management of priapism. Br J Urol 1982; 54:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/17\">",
"      Burnett AL. Pathophysiology of priapism: dysregulatory erection physiology thesis. J Urol 2003; 170:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/18\">",
"      Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med 2006; 3:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/19\">",
"      Muneer A, Minhas S, Arya M, Ralph DJ. Stuttering priapism--a review of the therapeutic options. Int J Clin Pract 2008; 62:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/20\">",
"      Champion HC, Bivalacqua TJ, Takimoto E, et al. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A 2005; 102:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/21\">",
"      Palese MA, Ferrer F, Perlman E, Gearhart JP. Metanephric stromal tumor: a rare benign pediatric renal mass. Urology 2001; 58:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/22\">",
"      Montague DK, Jarow J, Broderick GA, et al. American Urological Association guideline on the management of priapism. J Urol 2003; 170:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/23\">",
"      Kwok B, Varol C. Priapism and penile gangrene due to thrombotic thrombocytopenic purpura. Urology 2010; 75:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/24\">",
"      Metawea B, El-Nashar AR, Gad-Allah A, et al. Intracavernous papaverine/phentolamine-induced priapism can be accurately predicted with color Doppler ultrasonography. Urology 2005; 66:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/25\">",
"      Dittrich A, Albrecht K, Bar-Moshe O, Vandendris M. Treatment of pharmacological priapism with phenylephrine. J Urol 1991; 146:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/26\">",
"      Siegel JF, Reda E. Intracorporeal phenylephrine reduces thioridazine (Mellaril) induced priapism in a child. J Urol 1997; 157:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/27\">",
"      Munarriz R, Wen CC, McAuley I, et al. Management of ischemic priapism with high-dose intracavernosal phenylephrine: from bench to bedside. J Sex Med 2006; 3:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/28\">",
"      Roberts JR, Price C, Mazzeo T. Intracavernous epinephrine: a minimally invasive treatment for priapism in the emergency department. J Emerg Med 2009; 36:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/29\">",
"      Fuentes EJ, Garcia S, Garrido M, et al. Successful treatment of propofol-induced priapism with distal glans to corporal cavernosal shunt. Urology 2009; 74:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/30\">",
"      Chiou RK, Aggarwal H, Mues AC, et al. Clinical experience and sexual function outcome of patients with priapism treated with penile cavernosal-dorsal vein shunt using saphenous vein graft. Urology 2009; 73:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/31\">",
"      Nixon RG, O'Connor JL, Milam DF. Efficacy of shunt surgery for refractory low flow priapism: a report on the incidence of failed detumescence and erectile dysfunction. J Urol 2003; 170:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/32\">",
"      Brant WO, Garcia MM, Bella AJ, et al. T-shaped shunt and intracavernous tunneling for prolonged ischemic priapism. J Urol 2009; 181:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/33\">",
"      Rees RW, Kalsi J, Minhas S, et al. The management of low-flow priapism with the immediate insertion of a penile prosthesis. BJU Int 2002; 90:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/34\">",
"      Ralph DJ, Garaffa G, Muneer A, et al. The immediate insertion of a penile prosthesis for acute ischaemic priapism. Eur Urol 2009; 56:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/35\">",
"      Kang BC, Lee DY, Byun JY, et al. Post-traumatic arterial priapism: colour Doppler examination and superselective arterial embolization. Clin Radiol 1998; 53:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/36\">",
"      Bartsch G Jr, Kuefer R, Engel O, Volkmer BG. High-flow priapism: colour-Doppler ultrasound-guided supraselective embolization therapy. World J Urol 2004; 22:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/37\">",
"      O'Sullivan P, Browne R, McEniff N, Lee MJ. Treatment of \"high-flow\" priapism with superselective transcatheter embolization: a useful alternative to surgery. Cardiovasc Intervent Radiol 2006; 29:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/38\">",
"      Kuefer R, Bartsch G Jr, Herkommer K, et al. Changing diagnostic and therapeutic concepts in high-flow priapism. Int J Impot Res 2005; 17:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/39\">",
"      Shapiro RH, Berger RE. Post-traumatic priapism treated with selective cavernosal artery ligation. Urology 1997; 49:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/40\">",
"      Ricciardi R Jr, Bhatt GM, Cynamon J, et al. Delayed high flow priapism: pathophysiology and management. J Urol 1993; 149:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7127/abstract/41\">",
"      Brock G, Breza J, Lue TF, Tanagho EA. High flow priapism: a spectrum of disease. J Urol 1993; 150:968.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6887 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_61_7127=[""].join("\n");
var outline_f6_61_7127=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ischemic priapism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Recurrent priapism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nonischemic (high flow) priapism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cavernosal blood gas analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other blood studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Toxicology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Doppler ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment of ischemic priapism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment of recurrent priapism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treatment of nonischemic (high flow) priapism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H346924829\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6887\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6887|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?43/25/44446\" title=\"algorithm 1\">",
"      Mgmt algorithm priapism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6887|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/3/11319\" title=\"figure 1\">",
"      Anatomy of the penis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6887|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/1/13339\" title=\"table 1\">",
"      Etiology of priapism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/35/1595\" title=\"table 2\">",
"      Intracorporeal blood gas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23017?source=related_link\">",
"      Diagnosis and management of priapism in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=related_link\">",
"      Diagnosis of sickle cell syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/40/34433?source=related_link\">",
"      Patient information: Priapism (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_61_7128="Chronic migraine";
var content_f6_61_7128=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic migraine",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/61/7128/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/61/7128/contributors\">",
"     Ivan Garza, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/61/7128/contributors\">",
"     Todd J Schwedt, MD, MSCI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/61/7128/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/61/7128/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/61/7128/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/61/7128/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/61/7128/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic daily headache is a descriptive term that encompasses several different specific headache diagnoses characterized by frequent headaches. Chronic daily headache types with individual headaches of long duration (ie, four hours or more) include chronic migraine (",
"    <a class=\"graphic graphic_table graphicRef56064 \" href=\"UTD.htm?33/14/34027\">",
"     table 1",
"    </a>",
"    ), chronic tension-type headache (",
"    <a class=\"graphic graphic_table graphicRef68892 \" href=\"UTD.htm?38/22/39275\">",
"     table 2",
"    </a>",
"    ), medication overuse headache (",
"    <a class=\"graphic graphic_table graphicRef71798 \" href=\"UTD.htm?8/35/8763\">",
"     table 3",
"    </a>",
"    ), hemicrania continua (",
"    <a class=\"graphic graphic_table graphicRef62652 \" href=\"UTD.htm?29/56/30603\">",
"     table 4",
"    </a>",
"    ), and new daily persistent headache (",
"    <a class=\"graphic graphic_table graphicRef76010 \" href=\"UTD.htm?34/48/35595\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic will discuss chronic migraine (previously known as transformed migraine). Other types of chronic daily headache are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37830?source=see_link\">",
"     \"Overview of chronic daily headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of migraine centers on the trigeminovascular system. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H130649620#H130649620\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the pathophysiology of the transformation from episodic to chronic migraine is not well-understood, it is hypothesized that persistent neurogenic inflammation and central sensitization are involved. Furthermore, in patients with migraine, functional and structural alterations in the brain have been identified that correlate with longer disease duration and increased headache frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, it is not clear whether these alterations lead to chronic migraine. They may be simply markers of transformation or secondary effects from frequent migraines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic migraine affects approximately 2 percent of the world population [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/3\">",
"     3",
"    </a>",
"    ]. It causes significant reductions in quality of life and is even more disabling than episodic migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. In addition, chronic migraine results in enormous expense to society. In the United States, the direct and indirect costs of migraine are estimated to be more than 20 billion dollars annually, and a significant proportion of this cost is attributable to chronic migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Through a process known as \"migraine transformation\", some patients with an episodic migraine pattern (&lt;15 headache days a month) transition to a chronic migraine pattern (&ge;15 headache days a month) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/9\">",
"     9",
"    </a>",
"    ]. Among patients with episodic migraine, it is estimated that transformation to chronic migraine occurs each year in 3 to 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Non-modifiable risk factors for the transformation from episodic to chronic migraine include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/12-17\">",
"     12-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Female gender",
"     </li>",
"     <li>",
"      Genetic makeup",
"     </li>",
"     <li>",
"      History of head or neck injury",
"     </li>",
"     <li>",
"      Low education level",
"     </li>",
"     <li>",
"      Low socioeconomic status",
"     </li>",
"     <li>",
"      Stressful life events",
"     </li>",
"     <li>",
"      Younger age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Potentially modifiable risk factors for this transformation include [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/12-17\">",
"     12-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Overuse of abortive headache medications",
"     </li>",
"     <li>",
"      Depression",
"     </li>",
"     <li>",
"      Habitual snoring",
"     </li>",
"     <li>",
"      High caffeine consumption",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Sleep disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further study is needed to determine if altering modifiable risk factors decreases the rate of transformation to chronic migraine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with chronic migraine have a pattern of daily or near-daily headaches of low to moderate severity, associated with less prominent migrainous features. Superimposed on this baseline are exacerbations of pain with more prominent migrainous features such as photophobia, phonophobia, osmophobia, nausea, vomiting, and cutaneous allodynia (ie, the perception of pain produced by innocuous stimulation of normal skin). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H21674085#H21674085\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Comorbid conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In observational studies, patients with chronic migraine have a high frequency of comorbid psychiatric disorders, sleep disorders, fatigue, other types of pain, and gastrointestinal complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/18-24\">",
"     18-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, psychiatric comorbidities among 152 patients with transformed migraine included major depression, dysthymia, panic disorder, and generalized anxiety disorder, observed in 57, 11, 30, and 8 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In another study of 63 patients with chronic migraine, two-thirds meet criteria for chronic fatigue syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In a report of 101 patients with transformed migraine, the diagnostic criteria for fibromyalgia were fulfilled by 36 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In a sample of 1283 migraineurs who presented for evaluation to a tertiary headache clinic, patients with chronic migraine slept less than those with episodic migraine and were more likely to report difficulty falling and staying asleep [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Among 150 patients with chronic migraine complicated by probable medication overuse headache, the most common comorbidities were psychiatric and gastrointestinal, identified in 76 and 43 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recognition and treatment of these comorbidities can result in improved health, greater quality of life, and may potentially result in higher migraine treatment success rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of chronic migraine depends upon a consistent clinical history without evidence for another primary or secondary headache disorder.",
"   </p>",
"   <p>",
"    The 2004 ICHD 2 diagnostic criteria for chronic migraine required the presence of headache fulfilling the criteria for migraine without aura on &ge;15 days per month for more than three months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/25\">",
"     25",
"    </a>",
"    ]. A later modification required that only 8 of the 15 headaches per month fulfill criteria for migraine without aura [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/26\">",
"     26",
"    </a>",
"    ]. This revision allows for the inclusion of migraine headaches that are treated early after the onset, prior to the development of typical migraine characteristics, when they may resemble tension-type headaches.",
"   </p>",
"   <p>",
"    The following are the 2006 revised criteria for chronic migraine (",
"    <a class=\"graphic graphic_table graphicRef56064 \" href=\"UTD.htm?33/14/34027\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A) Headache (tension-type",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      migraine) on &ge;15 days per month for at least three months",
"     </li>",
"     <li>",
"      B) Occurring in a patient who has had at least five attacks fulfilling criteria for migraine without aura",
"     </li>",
"     <li>",
"      C) On &ge;8 days per month for at least three months, headache has fulfilled criteria C1",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      C2 below, that is, has fulfilled criteria for pain and associated symptoms of migraine without aura",
"     </li>",
"     <li>",
"      C1a) Headache has at least two of the following characteristics:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Unilateral location",
"     </li>",
"     <li>",
"      Pulsating quality",
"     </li>",
"     <li>",
"      Moderate or severe pain intensity",
"     </li>",
"     <li>",
"      Aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C1b) During headache, at least one of the following is present:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nausea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vomiting",
"     </li>",
"     <li>",
"      Photophobia and phonophobia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C2) Treated and relieved by triptan(s) or ergot before the expected development of associated symptoms of migraine",
"     </li>",
"     <li>",
"      D) No medication overuse and not attributed to another causative disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The criteria for chronic migraine will continue to evolve [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic migraine (",
"    <a class=\"graphic graphic_table graphicRef56064 \" href=\"UTD.htm?33/14/34027\">",
"     table 1",
"    </a>",
"    ) must be differentiated from other forms of chronic daily headache, such as chronic tension-type headache (",
"    <a class=\"graphic graphic_table graphicRef68892 \" href=\"UTD.htm?38/22/39275\">",
"     table 2",
"    </a>",
"    ), medication overuse headache (",
"    <a class=\"graphic graphic_table graphicRef71798 \" href=\"UTD.htm?8/35/8763\">",
"     table 3",
"    </a>",
"    ), hemicrania continua (",
"    <a class=\"graphic graphic_table graphicRef62652 \" href=\"UTD.htm?29/56/30603\">",
"     table 4",
"    </a>",
"    ), new daily persistent headache (",
"    <a class=\"graphic graphic_table graphicRef76010 \" href=\"UTD.htm?34/48/35595\">",
"     table 5",
"    </a>",
"    ), and secondary headaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37830?source=see_link\">",
"     \"Overview of chronic daily headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of chronic migraine should focus on prophylactic therapy while avoiding migraine triggers and minimizing the use of acute headache medications. Prophylactic interventions may include pharmacotherapy, behavioral therapy, physical therapy, and other strategies. Management often requires the simultaneous use of these different therapeutic modalities.",
"   </p>",
"   <p>",
"    Identification and treatment of comorbid disorders is also important. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Comorbid conditions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Acute headache medication intake should be limited in order to avoid medication overuse headache, but severe superimposed migraine headaches are treated in the same manner as episodic migraine headaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=see_link\">",
"     \"Acute treatment of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link\">",
"     \"Preventive treatment of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients and clinicians should have realistic treatment expectations with regard to chronic migraine. The overall goal is control of headaches as opposed to eradication. It is reasonable to expect reductions in headache frequency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity with a well considered treatment plan.",
"   </p>",
"   <p>",
"    The treatment of status migrainosus (a debilitating migraine attack lasting for &gt;72 hours) with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"     dihydroergotamine",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17161?source=see_link&amp;anchor=H11#H11\">",
"     \"Medication overuse headache: Treatment and prognosis\", section on 'Dihydroergotamine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive medications for chronic migraine treatment are less well-studied than they are for episodic migraine. In addition, most of the available controlled trials evaluating treatment of chronic migraine are limited by one or more methodologic problems, such as small size, inclusion of patients with overuse of acute headache medications, high dropout rates, concomitant use of other prophylactic medications,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lack of a specific headache diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     First-line agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In clinical practice, the same prophylactic medications used for episodic migraine are used for the prevention of chronic migraine. Thus, based mainly upon their efficacy and tolerability when treating episodic migraine (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link\">",
"     \"Preventive treatment of migraine in adults\"",
"    </a>",
"    ), first-line prophylactic medications for chronic migraine include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Beta blockers (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31776?source=see_link\">",
"       timolol",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       Amitriptyline",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       Topiramate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Valproic acid and its derivatives",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest that treatment for patients with chronic migraine begin with trials of one of these agents.",
"   </p>",
"   <p>",
"    It is expected that up to 50 percent of patients treated with one of these medications will have at least a 50 percent reduction in the frequency of headaches after three months of treatment, given adequate doses. However, side effects are common and may limit the use of these prophylactic agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Second-line agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with chronic migraine that is refractory to adequate trials of first-line agents, a number of other drugs are potential alternatives, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Botulinum toxin type A (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"       onabotulinumtoxinA",
"      </a>",
"      , Botox&reg;)",
"     </li>",
"     <li>",
"      Butterbur",
"     </li>",
"     <li>",
"      Calcium channel blockers",
"     </li>",
"     <li>",
"      Other beta blockers (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"       nadolol",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Feverfew",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       Fluoxetine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"       Levetiracetam",
"      </a>",
"     </li>",
"     <li>",
"      Magnesium",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"       Memantine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       Pregabalin",
"      </a>",
"     </li>",
"     <li>",
"      Riboflavin",
"     </li>",
"     <li>",
"      Serotonin-norepinephrine reuptake inhibitors",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/35/12855?source=see_link\">",
"       Tizanidine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While earlier randomized trials evaluating botulinum toxin injection for chronic migraine (&ge;15 headache days a month) or chronic daily headache yielded mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/32-34\">",
"     32-34",
"    </a>",
"    ], the findings from two relatively large 24-week multicenter randomized controlled trials (PREEMPT 1 AND PREEMPT 2) suggest that botulinum toxin type A (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    , Botox&reg;) is effective for the treatment of chronic migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Although the two PREEMPT trials used the same methods, they had different primary outcome measures.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In PREEMPT 1, there was no significant difference between groups for the primary outcome, frequency of headache episodes. However,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"       onabotulinumtoxinA",
"      </a>",
"      treatment was superior to placebo on some secondary outcome measures including the frequency of headache days and migraine days [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In PREEMPT 2,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"       onabotulinumtoxinA",
"      </a>",
"      treatment resulted in a larger reduction in number of headache days (the primary outcome measure) compared with placebo. OnabotulinumtoxinA was also superior to placebo on several secondary outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pooled analyses of data from the PREEMPT 1 and PREEMPT 2 trials, which together enrolled 1384 adults, found statistically significant differences favoring",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"       onabotulinumtoxinA",
"      </a>",
"      for a decrease in the frequency of headache days relative to baseline (the same primary outcome as PREEMPT 2) and for nearly all secondary outcomes except the frequency of acute headache pain medication intake [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. The rate of treatment discontinuation due to adverse events was higher for botulinum toxin than for placebo (3.8 versus 1.2 percent).",
"     </li>",
"     <li>",
"      There was a large response to placebo treatment in these trials, and the difference between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"       onabotulinumtoxinA",
"      </a>",
"      injection and placebo for many of the outcomes was modest, even if statistically significant [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/35-37\">",
"       35-37",
"      </a>",
"      ]. As an example, in the pooled analysis, treatment with onabotulinumtoxinA led to a statistically significant reduction of headache days per 28 days compared with placebo (8.4 versus 6.6), but the absolute difference between the two groups was small (1.8 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A majority (approximately 66 percent) of patients in both PREEMPT trials were overusing analgesic medications [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35879?source=see_link\">",
"       \"Medication overuse headache: Etiology, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, these data support the utility of botulinum toxin injection as moderately superior to placebo for the treatment of chronic migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/39\">",
"     39",
"    </a>",
"    ]. However, the need for an experienced clinician to administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    , and its high cost, have led us to consider it as second-line therapy. The effectiveness of the remaining second-line medications for episodic and chronic migraine is uncertain, as most have been studied only on a limited basis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link&amp;anchor=H6#H6\">",
"     \"Preventive treatment of migraine in adults\", section on 'Calcium channel blockers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link&amp;anchor=H13#H13\">",
"     \"Preventive treatment of migraine in adults\", section on 'Other agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest the use of these second-line agents for the prevention of chronic migraine when first-line drugs have failed. This recommendation is based upon our clinical experience. Like first-line agents, the choice among the second-line drugs depends upon individual patient factors, as discussed in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Choosing an agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of specific prophylactic agent for either episodic or chronic migraine depends upon individual patient factors, including the presence of comorbid conditions such as medical disorders, psychiatric disorders, sleep disorders, fatigue, other types of pain, and gastrointestinal complaints. As an example, tricyclics or other antidepressants may be preferred for patients who are depressed or prone to depression. On the other hand, beta blockers may be preferred for patients with hypertension. However, with some preventive agents, the doses used to treat migraine are insufficient to treat comorbid conditions. Thus, dosing may need to be adjusted if the intent is to treat a comorbid condition.",
"   </p>",
"   <p>",
"    Regardless of the drug chosen, application of certain principles may improve the success rate of prophylactic migraine therapy and reduce complications:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Start oral drugs at a low dose and increase gradually",
"     </li>",
"     <li>",
"      Give the chosen medication an adequate trial",
"     </li>",
"     <li>",
"      Avoid overuse of acute headache medications",
"     </li>",
"     <li>",
"      Avoid",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      for women of childbearing potential (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5114?source=see_link&amp;anchor=H5#H5\">",
"       \"Headache in pregnancy\", section on 'Prophylactic treatment'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Address patient expectations and preferences",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These points are discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link&amp;anchor=H30#H30\">",
"     \"Preventive treatment of migraine in adults\", section on 'Prophylactic principles'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Nonpharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic forms of therapy may be useful for the treatment of chronic migraine. Modalities include behavioral therapy (eg, biofeedback, cognitive-behavioral therapy, stress management, relaxation therapy) and physical therapy (eg, exercise, heat, cold packs, electrical stimulation). In addition, therapeutic lifestyle changes (good sleep hygiene, routine meal schedules, regular exercise) and avoidance of migraine triggers are often advocated for patients with chronic migraine. However, there is a paucity of high-quality studies examining the role of nonpharmacologic interventions specifically for chronic migraine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Avoidance of migraine triggers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic migraine are more likely to have headaches triggered by stress, not eating, odors, neck pain, smoke, sleeping late, and exercise than patients with episodic migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/40\">",
"     40",
"    </a>",
"    ]. These are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H21674092#H21674092\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Precipitating and exacerbating factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Avoidance of specific migraine triggers may reduce the frequency of headaches in patients with chronic migraine. Of course, patients with continuous headaches are less likely to be able to determine specific migraine triggers than those who have episodic headaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Behavioral and physical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In agreement with guidelines for migraine headache (mainly based upon studies of episodic migraine) from the American Academy of Neurology (AAN) published in 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/41\">",
"     41",
"    </a>",
"    ], we suggest the use of behavioral therapy for migraine prevention. Options include relaxation training, thermal biofeedback combined with relaxation training, electromyographic biofeedback, or cognitive-behavioral therapy. The choice among these interventions should be individualized according to factors that include clinician familiarity, local availability and expertise, and patient preference.",
"   </p>",
"   <p>",
"    In our clinical experience, physical therapy may be useful for the treatment of chronic migraine in patients who have constant muscle tension or in those who report onset of muscle tension preceding migraine headaches. Of note, the AAN guidelines concluded that evidence-based recommendations could not be made regarding the use of hypnosis, acupuncture, transcutaneous electrical nerve stimulation, chiropractic or osteopathic cervical manipulation, occlusal adjustment, or hyperbaric oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both behavioral therapy and physical therapy may be combined with each other",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    with preventive drug therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H634848644\">",
"    <span class=\"h3\">",
"     Occipital nerve stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are inconsistent data from small randomized trials regarding the benefit of occipital nerve stimulation for the treatment of chronic migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In the largest trial, there was no significant difference at 12 weeks for the primary endpoint, the percentage of patients that had a &ge;50 percent reduction in mean daily pain score in the active compared with the control group [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/43\">",
"     43",
"    </a>",
"    ]. However, there were statistically significant if modest improvements with active stimulation for a number of secondary endpoints, including the percentage of patients with a &ge;30 percent reduction in mean daily pain score, and reduction in the mean number of headache days and migraine-related disability. The findings from these reports are limited by concerns about blinding in the control (sham treatment) groups, given that active treatment causes paresthesia, and relatively high rates of complications, including lead migration in 14 to 24 percent of subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]. Further trials are needed to determine if occipital nerve stimulation is a useful therapy for chronic migraine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic migraine may revert to episodic migraine over time in 26 to 70 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest study, conducted by mailed questionnaire, followed 383 respondents with chronic migraine [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/47\">",
"       47",
"      </a>",
"      ]. After two years, chronic migraine had remitted to either low frequency episodic migraine (&le;9 headache",
"      <span class=\"nowrap\">",
"       days/month),",
"      </span>",
"      other episodic headache, or no headache in 26 percent. Predictors of remission were lower baseline headache frequency and absence of allodynia.",
"     </li>",
"     <li>",
"      Another report evaluated 136 patients with transformed (ie, chronic) migraine who presented to a specialty headache clinic and were followed for one year [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7128/abstract/46\">",
"       46",
"      </a>",
"      ]. Reversion to episodic migraine from transformed migraine was observed in 95 patients (70 percent). Predictors of reversion included complete withdrawal of overused medications, compliance with prophylactic medication regimens, and regular physical exercise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Through a process known as \"migraine transformation\", some patients with an episodic migraine pattern transition to a chronic migraine pattern (&ge;15 headache days a month). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many patients with chronic migraine have daily or near-daily headaches of low to moderate severity. Superimposed on this baseline are exacerbations of pain with more prominent migrainous features. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Observational evidence suggests that patients with chronic migraine have a high frequency of comorbid psychiatric disorders, sleep disorders, fatigue, other types of pain, and gastrointestinal complaints. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of chronic migraine depends upon a consistent clinical history and exclusion of secondary headache disorders (",
"      <a class=\"graphic graphic_table graphicRef56064 \" href=\"UTD.htm?33/14/34027\">",
"       table 1",
"      </a>",
"      ). Chronic migraine also must be differentiated from other forms of long-duration primary chronic daily headache, including chronic tension-type headache (",
"      <a class=\"graphic graphic_table graphicRef68892 \" href=\"UTD.htm?38/22/39275\">",
"       table 2",
"      </a>",
"      ), medication overuse headache (",
"      <a class=\"graphic graphic_table graphicRef71798 \" href=\"UTD.htm?8/35/8763\">",
"       table 3",
"      </a>",
"      ), hemicrania continua (",
"      <a class=\"graphic graphic_table graphicRef62652 \" href=\"UTD.htm?29/56/30603\">",
"       table 4",
"      </a>",
"      ), and new daily persistent headache (",
"      <a class=\"graphic graphic_table graphicRef76010 \" href=\"UTD.htm?34/48/35595\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of chronic migraine should focus on prophylactic therapy and avoidance of acute headache medication overuse. Prophylactic interventions may include pharmacotherapy, behavioral therapy, physical therapy, lifestyle modification (good sleep hygiene, routine meal schedules, regular exercise), and avoidance of migraine triggers. Management often requires the simultaneous use of these different therapeutic modalities. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with chronic migraine who desire pharmacologic treatment, we suggest a trial with one of the first-line prophylactic migraine medications (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). First-line prophylactic agents are beta blockers (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31776?source=see_link\">",
"       timolol",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      , and valproic acid and its derivatives. The choice among migraine prophylactic agents depends upon individual patient factors and comorbid conditions. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'First-line agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Choosing an agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Second-line pharmacologic agents for chronic migraine include botulinum toxin injections, Butterbur, calcium channel blockers, other beta blockers, feverfew,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"       levetiracetam",
"      </a>",
"      , magnesium,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"       memantine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      , riboflavin, serotonin-norepinephrine reuptake inhibitors, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/35/12855?source=see_link\">",
"       tizanidine",
"      </a>",
"      . Botulinum toxin injections are modestly superior to placebo for the treatment of chronic migraine. The remaining drugs have been studied only on a limited basis, and their effectiveness in migraine prophylaxis is uncertain. For patients with chronic migraine who have failed treatment with first-line agents, we suggest use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"       onabotulinumtoxinA",
"      </a>",
"      injections (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) or other second line agents (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Second-line agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with chronic migraine who desire nonpharmacologic therapy, we suggest behavioral therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Options include relaxation training, thermal biofeedback combined with relaxation training, electromyographic biofeedback, or cognitive-behavioral therapy. As with medications, the choice among these interventions should be individualized. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Behavioral and physical therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/1\">",
"      Schwedt TJ, Dodick DW. Advanced neuroimaging of migraine. Lancet Neurol 2009; 8:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/2\">",
"      Aurora SK. Is chronic migraine one end of a spectrum of migraine or a separate entity? Cephalalgia 2009; 29:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/3\">",
"      Castillo J, Mu&ntilde;oz P, Guitera V, Pascual J. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache 1999; 39:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/4\">",
"      Guitera V, Mu&ntilde;oz P, Castillo J, Pascual J. Quality of life in chronic daily headache: a study in a general population. Neurology 2002; 58:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/5\">",
"      D'Amico D, Usai S, Grazzi L, et al. Quality of life and disability in primary chronic daily headaches. Neurol Sci 2003; 24 Suppl 2:S97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/6\">",
"      Harwood RH, Sayer AA, Hirschfeld M. Current and future worldwide prevalence of dependency, its relationship to total population, and dependency ratios. Bull World Health Organ 2004; 82:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/7\">",
"      Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008; 71:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/8\">",
"      Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003; 290:2443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/9\">",
"      Lipton RB. Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurology 2009; 72:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/10\">",
"      Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache 1998; 38:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/11\">",
"      Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004; 62:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/12\">",
"      Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003; 106:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/13\">",
"      Couch JR, Lipton RB, Stewart WF, Scher AI. Head or neck injury increases the risk of chronic daily headache: a population-based study. Neurology 2007; 69:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/14\">",
"      Scher AI, Stewart WF, Lipton RB. Caffeine as a risk factor for chronic daily headache: a population-based study. Neurology 2004; 63:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/15\">",
"      Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache 2006; 46:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/16\">",
"      Cevoli S, Sancisi E, Pierangeli G, et al. Chronic daily headache: risk factors and pathogenetic considerations. Neurol Sci 2006; 27 Suppl 2:S168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/17\">",
"      Bigal ME, Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. Neurology 2008; 71:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/18\">",
"      Tietjen GE, Brandes JL, Digre KB, et al. High prevalence of somatic symptoms and depression in women with disabling chronic headache. Neurology 2007; 68:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/19\">",
"      Verri AP, Proietti Cecchini A, Galli C, et al. Psychiatric comorbidity in chronic daily headache. Cephalalgia 1998; 18 Suppl 21:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/20\">",
"      Juang KD, Wang SJ, Fuh JL, et al. Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtypes. Headache 2000; 40:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/21\">",
"      Peres MF, Zukerman E, Young WB, Silberstein SD. Fatigue in chronic migraine patients. Cephalalgia 2002; 22:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/22\">",
"      Peres MF, Young WB, Kaup AO, et al. Fibromyalgia is common in patients with transformed migraine. Neurology 2001; 57:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/23\">",
"      Kelman L, Rains JC. Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs. Headache 2005; 45:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/24\">",
"      Ferrari A, Leone S, Vergoni AV, et al. Similarities and differences between chronic migraine and episodic migraine. Headache 2007; 47:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/25\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/26\">",
"      Headache Classification Committee, Olesen J, Bousser MG, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/27\">",
"      Sun-Edelstein C, Bigal ME, Rapoport AM. Chronic migraine and medication overuse headache: clarifying the current International Headache Society classification criteria. Cephalalgia 2009; 29:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/28\">",
"      Dodick DW. Clinical practice. Chronic daily headache. N Engl J Med 2006; 354:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/29\">",
"      Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/30\">",
"      Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/31\">",
"      Saper JR, Lake AE 3rd, Cantrell DT, et al. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache 2002; 42:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/32\">",
"      Freitag FG, Diamond S, Diamond M, Urban G. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse. Headache 2008; 48:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/33\">",
"      Mathew NT, Frishberg BM, Gawel M, et al. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005; 45:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/34\">",
"      Silberstein SD, Stark SR, Lucas SM, et al. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005; 80:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/35\">",
"      Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/36\">",
"      Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/37\">",
"      Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/38\">",
"      Lipton RB, Varon SF, Grosberg B, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology 2011; 77:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/39\">",
"      Schoenen J. Botulinum toxin in headache treatment: finally a promising path? Cephalalgia 2010; 30:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/40\">",
"      Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia 2007; 27:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/41\">",
"      Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/42\">",
"      Saper JR, Dodick DW, Silberstein SD, et al. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 2011; 31:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/43\">",
"      Silberstein SD, Dodick DW, Saper J, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia 2012; 32:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/44\">",
"      Schwedt TJ. Occipital nerve stimulation for chronic migraine--interpreting the ONSTIM feasibility trial. Cephalalgia 2011; 31:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/45\">",
"      Diener HC. Occipital nerve stimulation for chronic migraine: already advised? Cephalalgia 2012; 32:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/46\">",
"      Seok JI, Cho HI, Chung CS. From transformed migraine to episodic migraine: reversion factors. Headache 2006; 46:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7128/abstract/47\">",
"      Manack A, Buse DC, Serrano D, et al. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology 2011; 76:711.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3337 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-125.39.66.147-B9BF6B98CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_61_7128=[""].join("\n");
var outline_f6_61_7128=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - First-line agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Second-line agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Choosing an agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Avoidance of migraine triggers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Behavioral and physical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H634848644\">",
"      - Occipital nerve stimulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/3337\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3337|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/14/34027\" title=\"table 1\">",
"      Chronic migraine diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/22/39275\" title=\"table 2\">",
"      Chronic tension-type headache criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/35/8763\" title=\"table 3\">",
"      Medication overuse headache criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/56/30603\" title=\"table 4\">",
"      Hemicrania continua diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/48/35595\" title=\"table 5\">",
"      New daily persistent headache criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=related_link\">",
"      Acute treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5114?source=related_link\">",
"      Headache in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35879?source=related_link\">",
"      Medication overuse headache: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17161?source=related_link\">",
"      Medication overuse headache: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37830?source=related_link\">",
"      Overview of chronic daily headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_61_7129="Noma (cancrum oris)";
var content_f6_61_7129=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Noma (cancrum oris)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/61/7129/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/61/7129/contributors\">",
"     Cyril O Enwonwu, ScD, PhD, MDS, BDS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/61/7129/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/61/7129/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/61/7129/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/61/7129/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/61/7129/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noma is a severe disfiguring gangrene of the mouth and face that starts as a gingival ulcer and spreads rapidly through the tissues of the mouth and face [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Unlike other infectious processes of the face, which may progress along anatomic spaces of the head and neck, noma can disrupt anatomic barriers and spread through muscle and bone [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/4\">",
"     4",
"    </a>",
"    ]. The resulting gangrene may involve the maxilla, the mandible, and extend to the nose and infra-orbital margins (",
"    <a class=\"graphic graphic_picture graphicRef70829 \" href=\"UTD.htm?7/56/8066\">",
"     picture 1",
"    </a>",
"    ). The word noma derives from the Greek \"voun\", meaning to devour, emphasizing the rapid progression of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noma is categorized by the World Health Organization (WHO) as a necrotizing ulcerative stomatitis. Synonyms include cancrum oris and fusospirochetal gangrene. The name \"cancrum oris\" was introduced in Britain in the mid-17",
"    <sup>",
"     th",
"    </sup>",
"    century and is still in common usage in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. According to an 1848 description, orofacial noma is a \"gangrenous affection of the mouth, especially attacking children in whom the constitution is altered by bad hygiene and serious illness, especially from the eruptive fevers, beginning as an ulcer of the mucous membrane, with edema of the face, extending from within out, rapidly destroying the soft parts and the bone, and almost always quickly fatal\" [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mortality can be reduced with prompt, appropriate treatment, though noma remains one of the most devastating and disfiguring human diseases worldwide and has been designated a health priority by the WHO [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/3,9-12\">",
"     3,9-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noma is a polymicrobial infection associated predominantly with anaerobic organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/3,13\">",
"     3,13",
"    </a>",
"    ]. Fusobacterium necrophorum has been observed most frequently in culture and appears to be an important organism for the development of noma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. Virulence factors of F. necrophorum include proteolytic enzymes and toxins capable of tissue destruction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/17\">",
"     17",
"    </a>",
"    ]. F. necrophorum also produces a growth stimulating factor for Prevotella intermedia, which facilitates lipid degradation.",
"   </p>",
"   <p>",
"    Other microorganisms cultivated from noma lesions among Nigerian children are similar to those seen in adult periodontitis and are also capable of releasing enzymes that can degrade host tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/18\">",
"     18",
"    </a>",
"    ]. These include Prevotella intermedia, alpha-hemolytic streptococci, Pseudomonas spp, Actinomyces spp, and Peptostreptococci micros [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/3,14-17,19-21\">",
"     3,14-17,19-21",
"    </a>",
"    ]. Spirochetes have also been observed at the advancing edge of active lesions with dark-field microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/14\">",
"     14",
"    </a>",
"    ]. Molecular studies have demonstrated the complex diversity of microorganisms associated with noma, including 67 bacterial species of which 25 have not yet been grown in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/22\">",
"     22",
"    </a>",
"    ]. Herpes viruses have also been implicated, particularly herpes simplex virus and cytomegalovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/1,20,23-25\">",
"     1,20,23-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The global distribution of noma is poorly understood. Many affected individuals die in the acute stage of the disease before presenting for clinical attention, many reside in rural areas, and some hide deliberately because of the stigma associated with the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/3,9,26\">",
"     3,9,26",
"    </a>",
"    ]. It is estimated that only about 10 percent of patients seek care during the acute stage of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/2,5,9,12,26,27\">",
"     2,5,9,12,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of noma is highest in sub-Saharan Africa; the disease also occurs in Asia and Latin America [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/6,9,12,26,28-30\">",
"     6,9,12,26,28-30",
"    </a>",
"    ]. The WHO estimates the annual global incidence of noma to be around 100,000 to 140,000 new cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/31\">",
"     31",
"    </a>",
"    ]. In countries such as Gambia, Niger, Nigeria, and Senegal, the annual incidence of noma based on hospital records ranges from 0.28 to 1.9 per 1000 children [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/26,32,33\">",
"     26,32,33",
"    </a>",
"    ]. In West Africa, the peak age range for acute illness is one to six years, although late stages do occur in adolescents and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/3,5,6,9,34\">",
"     3,5,6,9,34",
"    </a>",
"    ]. The fatality rate in the absence of treatment is about 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/31\">",
"     31",
"    </a>",
"    ]. With appropriate treatment, mortality rates are less than 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/5,9\">",
"     5,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    epidemic has been associated with an increase in the number of noma cases in developing and developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/1,7,35,36\">",
"     1,7,35,36",
"    </a>",
"    ]. Among 48 patients with noma seen at the University of Zimbabwe between 2002 and 2006, all were seropositive for HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noma occurred worldwide until the early 20",
"    <sup>",
"     th",
"    </sup>",
"    century, when it essentially disappeared from the developed countries; some cases occurred in concentration camps during World War II [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. The near eradication of noma from developed countries coincided with improvements in living standards, prior to the discovery of penicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/2,6,9\">",
"     2,6,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poverty is a critical risk factor for noma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/1,6,34,40\">",
"     1,6,34,40",
"    </a>",
"    ]. Additional associated factors include malnutrition, poor sanitation, poor oral hygiene, limited access to healthcare services, close residential proximity to livestock, nomadic lifestyle, and high prevalence of infectious diseases including malaria, measles, AIDS, diarrhea, and tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/3,9,24,40\">",
"     3,9,24,40",
"    </a>",
"    ]. Infants and children are particularly susceptible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Malnutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic malnutrition is common in communities at risk for noma, as it increases susceptibility to infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/3,16,26,34,41\">",
"     3,16,26,34,41",
"    </a>",
"    ]. Dietary deficiencies of essential amino acids, omega-3 fatty acid, and micronutrients are frequently observed among malnourished individuals. The developing immune system is influenced by many of these nutrients during the prenatal period [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/3,42-45\">",
"     3,42-45",
"    </a>",
"    ]. The prevalence of intrauterine growth retardation leading to infants who are small for gestational age (SGA) is high in communities at risk for noma; the infant mortality rate in such settings may be as high as 114 per 1000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/34,46,47\">",
"     34,46,47",
"    </a>",
"    ]. SGA infants have compromised thymic function that may persist through adolescence to adult life [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/3,48-50\">",
"     3,48-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Acute necrotizing gingivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute necrotizing gingivitis (ANG) is an important risk condition for noma. ANG is characterized by ulceration involving one or more interdental papillae, pain, fetid breath, bad taste, fever, and lymphadenopathy (",
"    <a class=\"graphic graphic_picture graphicRef64614 \" href=\"UTD.htm?21/18/21793\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/25,51,52\">",
"     25,51,52",
"    </a>",
"    ]. The most common sites of ANG are the premolar and molar area, followed by the mandibular incisor area. Ulceration of the overlapping inner cheek may also occur.",
"   </p>",
"   <p>",
"    In sub-Saharan Africa, ANG typically occurs among malnourished children two to six years of age. The prevalence ranges from 2 to 18 percent in some rural communities [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/3,9,26,53\">",
"     3,9,26,53",
"    </a>",
"    ]. In developed settings, ANG is rare; it is occasionally observed in severely immunocompromised individuals such as patients with HIV infection and those receiving organ transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/25,51,54\">",
"     25,51,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with noma, ANG is likely attributable to periodontal bacteria and herpesviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/23,55,56\">",
"     23,55,56",
"    </a>",
"    ]. Cytomegalovirus appears to promote release of inflammatory mediators as well as growth of anaerobic microorganisms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/53,55\">",
"     53,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional risk factors for noma include antecedent infection (particularly measles and malaria) and immunosuppressing conditions.",
"   </p>",
"   <p>",
"    Measles infection alters cytokine activity leading to immunosuppression that can persist up to six months after acute infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/57-60\">",
"     57-60",
"    </a>",
"    ]. The complications of measles in malnourished children include diarrhea, pneumonia, malnutrition, and stomatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/24,34,61\">",
"     24,34,61",
"    </a>",
"    ]. Stomatitis promotes reactivation of latent herpes viruses and may result in peribuccal, perinasal, and infra-orbital ulcerative lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/24,61-63\">",
"     24,61-63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Malaria infection also alters cytokine activity leading to immune impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. Cases of noma following malaria have been described in Nigeria and Turkey [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/36,40,67\">",
"     36,40,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noma has been described in the following clinical circumstances (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/60/8137?source=see_link\">",
"     \"Systemic conditions associated with periodontal disease in children\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       HIV-infection/AIDS",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/37,68-70\">",
"       37,68-70",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Type 2 diabetes mellitus [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/71\">",
"       71",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Immune deficient states such as familial neutropenia, histiocytosis syndromes, and severe combined immunodeficiency (SCID) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/19,72-76\">",
"       19,72-76",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Immunosuppressive therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/77\">",
"       77",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Autoimmune diseases in the absence of immunosuppressive therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/72\">",
"       72",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hypophosphatasia (an inborn error of metabolism caused by deficiency of tissue-nonspecific alkaline phosphatase) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/74\">",
"       74",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of noma is based on clinical manifestations. Suggestive clues include recent or concurrent infection preceding onset of facial swelling and excessive salivation in the setting of malnutrition. In general, there are three stages of noma (which may overlap): an acute phase, a gangrenous phase, and a scarring phase [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/4,6,9,17\">",
"     4,6,9,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acute phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms associated with the acute phase of noma include mouth soreness, facial swelling, fetid breath, excessive salivation, and difficulty eating [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/5,9,10\">",
"     5,9,10",
"    </a>",
"    ]. The medical history is frequently notable for recent or concurrent infections such as diarrheal illness, malaria, measles, tuberculosis, or HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/3,6,9,23,78\">",
"     3,6,9,23,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, children with acute noma are malnourished, as evidenced by growth retardation, hair discoloration,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    limb edema [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/2,24\">",
"     2,24",
"    </a>",
"    ]. In one study of Nigerian children &lt;4 years of age with acute noma, about 90 percent had stunted growth and were underweight; more than two-thirds were severely affected [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/34\">",
"     34",
"    </a>",
"    ]. Among age- and sex-matched neighborhood children without noma, about 40 percent were stunted and underweight; less than one-third were severely affected [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory findings may include severe anemia (hemoglobin levels as low as 5 to 6",
"    <span class=\"nowrap\">",
"     g/dL),",
"    </span>",
"    white blood cell counts of 20,000 to 30,000 per microL, and hypoalbuminemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/2,24,79\">",
"     2,24,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Gangrenous phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noma likely begins as a gingival inflammatory lesion that spreads to the labiogingival fold and then to the mucosal surface of the cheek and lip [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Subsequently an area of bluish-black discoloration may appear on the cheek (",
"    <a class=\"graphic graphic_picture graphicRef70829 \" href=\"UTD.htm?7/56/8066\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/5,27\">",
"     5,27",
"    </a>",
"    ]. After this finding appears, progression of disease resulting in perforation of the cheek is very rapid (usually a matter of days) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/1,2,5,27\">",
"     1,2,5,27",
"    </a>",
"    ]. During this time, there is extensive intraoral destruction (",
"    <a class=\"graphic graphic_picture graphicRef62639 \" href=\"UTD.htm?22/51/23345\">",
"     picture 3",
"    </a>",
"    ). Soft tissue sloughing leaves a well demarcated deep wound with exposed bones and teeth. Ulcerative gingivitis or periodontitis is considered to have progressed to noma once there is exposure of the alveolar bone [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/2,61\">",
"     2,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disease is usually unilateral but can occur bilaterally. Some cases may occur with ectopic lesions involving the scalp, neck, shoulders, perineum, and vulva [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/5,80\">",
"     5,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Scarring phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scarring sets in following the acute and gangrenous stages, leading to trismus and severe facial disfigurement [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/27,60,68\">",
"     27,60,68",
"    </a>",
"    ]. Sequelae of noma depend on the sites affected and the extent of tissue destruction; they may include displacement or exfoliation of teeth, facial mutilation, bony fusion between the maxilla and mandible, trismus, poor speech, and difficulty feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/5,27,60\">",
"     5,27,60",
"    </a>",
"    ]. Persistent leakage of saliva is a major problem in patients with extensive destruction of the maxilla, lower lip, cheek,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    floor of the mouth [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tissue defects may be evaluated using the NOITULP classification (Nose, Outer cheek, Inner cheek, Trismus, Upper lip, Lower lip, and Particularities) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/60,81\">",
"     60,81",
"    </a>",
"    ]. Particularities refer to additional manifestations such as loss of lower eyelid tissue; involvement of the orbit, skin of the chin; and defects of the maxillary sinus or palate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of noma is not fully understood. The following sections summarize observed findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathology generally demonstrates necrosis of the epidermis with acanthosis around the rim of the epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/4,27,77\">",
"     4,27,77",
"    </a>",
"    ]. The necrotic area is well circumscribed; at the margins there is hyperplasia with ballooning of the epithelial cells. The dermis typically has a heavy infiltrate of polymorphonuclear neutrophils; phagocytosed bacteria may be observed. Separation of collagen bundles due to edema may be observed. Blood vessels are frequently dilated and filled with inflammatory cells. Small and large cocci of various morphologies and gram-negative cocci-bacilli may be seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Role of malnutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noma is associated with very low levels of most essential amino acids and significant reductions in plasma levels of vitamin A, vitamin C, zinc, albumin, and hemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/16,24,28,42,79,82-84\">",
"     16,24,28,42,79,82-84",
"    </a>",
"    ]. Given the frequency of multiple concurrent deficiencies, no single nutrient deficiency has been causally related.",
"   </p>",
"   <p>",
"    Leptin, a polypeptide produced by adipose tissue involved in the inflammatory response and immune function, is significantly diminished in children with noma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/85-88\">",
"     85-88",
"    </a>",
"    ]. The prolonged inflammatory response in the setting of noma may downregulate or exhaust leptin production; similar observations have been described in the setting of tuberculosis with associated wasting and chronic inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Inflammatory mediators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with noma have higher inflammatory cytokine levels than neighborhood village children without noma; both groups have higher levels than age-matched healthy urban children [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/16\">",
"     16",
"    </a>",
"    ]. In the setting of noma, there appears to be disruption of complex interactions involving TNF and the TNF family receptor herpes virus entry mediator (HVEM), leading to T cell stimulation and promotion of mucosal inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/90-92\">",
"     90-92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The circulating cytokine patterns observed in children with noma resemble findings in other diseases characterized by necrotic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/16\">",
"     16",
"    </a>",
"    ]. Increased mucosal and systemic concentrations of many cytokines (particularly TNF and IL-18) are significantly elevated in noma and inflammatory bowel disease as well as measles, malaria, and sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/16,34,93-100\">",
"     16,34,93-100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of noma is straightforward in the gangrenous stage [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/101\">",
"     101",
"    </a>",
"    ]. The disease is readily recognized by the rapid course of inflammation in the setting of antecedent infection (measles, malaria, tuberculosis, etc). Diseases with similar characteristics include (see related topics):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Noma neonatorum &mdash; Noma neonatorum resembles noma in children but occurs during the first few weeks of life in premature and low birth weight infants [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/102-105\">",
"       102-105",
"      </a>",
"      ]. The gangrene generally involves the oronasal region, eyelids, and perineum. Cultures may demonstrate Pseudomonas aeruginosa, Escherichia coli, Klebsiella spp, or staphylococci.",
"     </li>",
"     <li>",
"      Ecthyma gangrenosum &mdash; Ecthyma gangrenosum resembles noma histopathologically. Like noma neonatorum, ecthyma may involve the oral cavity, nose, and perineum. Cultures usually demonstrate P. aeruginosa [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mycobacterial infection &mdash; Buruli ulcer due to M. ulcerans infection usually occurs on exposed areas, particularly the lower limbs [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/107,108\">",
"       107,108",
"      </a>",
"      ]. It typically presents with indolent, painless, undermined ulcers; the prevalence is highest in West Africa. Tuberculosis and leprosy may present with oral ulceronecrotic lesions.",
"     </li>",
"     <li>",
"      Mucocutaneous leishmaniasis &mdash; Mucocutaneous leishmaniasis causes disfiguring destruction of the mucous membranes of the nose, mouth. The majority of cases occur in South America, particularly Bolivia, Brazil, and Peru [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral and maxillofacial myiasis &mdash; Oral myiasis may cause a lesion resembling noma in adults and the elderly. It is caused by deposition of larval flies (eg, Diptera family Sarcophagidae) in pre-existing wounds such as in leprosy, traumatic injury, or skin carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/110,111\">",
"       110,111",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Craniocervical necrotizing fasciitis &mdash; Craniocervical necrotizing fasciitis originating from odontogenic abscess may lead to gangrene of the cheek in elderly individuals with diabetes mellitus [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/112,113\">",
"       112,113",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other entities that may resemble noma include Ludwig's angina, malignant oral lesions, or syphilis; these generally occur among adults [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute treatment of noma consists of antibiotics, wound care, and replacement of needed fluids, electrolytes, and nutrition. Several months to one year after the acute phase, surgery is performed for correction of trismus and flap creation. Physiotherapy to reduce fibrous scarring should be initiated during the healing phase and continued after surgery. Given the cosmetic and functional debilitation associated with noma, attention to psychosocial needs is also an important component of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to antimicrobial therapy is uncertain. The dose and type of antibiotic depend on individual circumstances and available clinical tools. Reasonable regimens include penicillin in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/9,77,114\">",
"     9,77,114",
"    </a>",
"    ]. Others prefer monotherapy with metronidazole since noma is associated predominantly with anaerobic organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/10,114\">",
"     10,114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For children who can swallow oral medication, antibiotics may be given in tablet or syrup form. Dosing for penicillin VK is 25 to 50",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    in three divided doses; dosing for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    is 30",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    in three or four divided doses. For children who cannot tolerate oral medication, parenteral therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12661?source=see_link\">",
"     penicillin G Procaine",
"    </a>",
"    may be administered. Dosing is 25,000 to 50,000",
"    <span class=\"nowrap\">",
"     units/kg/day",
"    </span>",
"    in divided doses one to two",
"    <span class=\"nowrap\">",
"     times/day,",
"    </span>",
"    not to exceed 4.8 million",
"    <span class=\"nowrap\">",
"     units/24",
"    </span>",
"    hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Wound care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meticulous attention to wound care is necessary to reduce the likelihood of secondary infection. The wound should be dressed daily with gauze soaked in antiseptic [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/9,10,27\">",
"     9,10,27",
"    </a>",
"    ]. If possible, the mouth should be rinsed with a solution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    digluconate (0.12 to 0.20%) daily [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. This may be continued for up to one week.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Fluid, electrolytes and nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of acute noma requires rehydration with correction of electrolyte abnormalities followed by nutritional rehabilitation with a high protein diet enriched with essential micronutrients. At the Noma Children Hospital in Sokoto, Nigeria, a highly enriched nutrition formula (Enfortal, donated through the Dutch Noma Foundation) has yielded good results [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/60\">",
"     60",
"    </a>",
"    ]. Feeding by mouth is preferred. If this is not possible due to pain, tissue destruction, or severe trismus, parenteral nutrition may be administered [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/5,27,60\">",
"     5,27,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=see_link\">",
"     \"Maintenance fluid therapy in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=see_link\">",
"     \"Oral rehydration therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11529?source=see_link\">",
"     \"Enteral nutrition in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Surgical repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of surgery is to improve cosmetic appearance as well as oral functions including eating, drinking, swallowing and speech [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/5,9,10,27,81\">",
"     5,9,10,27,81",
"    </a>",
"    ]. In the acute phase, intervention for control of secondary hemorrhage, removal of loose teeth, and wound debridement may be needed to prevent secondary infection and promote healing [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/68\">",
"     68",
"    </a>",
"    ]. To allow time for resolution of necrosis, more definitive surgery is performed several months to one year after the acute phase.",
"   </p>",
"   <p>",
"    The techniques for correction of deformities depend on location and severity of the lesions, available resources, and abilities of the surgical team [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/60,81,115\">",
"     60,81,115",
"    </a>",
"    ]. Preoperative classification of the tissue defects is essential for planning surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/5,9,81\">",
"     5,9,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial surgical intervention entails correction of trismus if present. This requires radical excision of fibrous bands restricting jaw opening [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/5,9,27,81,114-117\">",
"     5,9,27,81,114-117",
"    </a>",
"    ]. Thereafter, various flap techniques may be employed; options range from simple flaps and autoplasty to complex procedures involving microsurgery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/5,81,117,118\">",
"     5,81,117,118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These procedures require general anesthesia with intubation, which may be difficult in settings with limited facilities [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/81,114,119\">",
"     81,114,119",
"    </a>",
"    ]. Regional centers for noma surgical rehabilitation have been established in a number of developing countries, including the Noma Children Hospital (Sokoto, Nigeria), Stiftung Kinderhilfe (a German NGO), and the Dutch Noma Foundation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/60\">",
"     60",
"    </a>",
"    ]. Another organization, the German Hilfsaktion Noma, treats some cases in the Niger Republic and transfers very difficult cases to Germany.",
"   </p>",
"   <p>",
"    Following surgical repair, some functional and cosmetic defects may persist. Therefore, attention to psychosocial needs is also an important component of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/114,117\">",
"     114,117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should undergo evaluation of and treatment for predisposing systemic diseases including malaria, measles, tuberculosis, and HIV infection. Records of routine immunizations against endemic diseases should be verified.",
"   </p>",
"   <p>",
"    Physiotherapy to reduce fibrous scarring should be initiated during the healing phase and continued after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/115\">",
"     115",
"    </a>",
"    ]. If formal physiotherapy is not available, wooden spatulas may be used to keep the mouth open; an alternative device is the therabite (Atos Medical, Germany) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following surgical repair, some functional and cosmetic defects may persist. Therefore, attention to psychosocial needs is also an important component of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7129/abstract/114,117\">",
"     114,117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of noma requires a multidisciplinary approach with attention to routine healthcare needs, sanitation, nutrition, and public awareness.",
"   </p>",
"   <p>",
"    Health personnel should know the risk factors for and early signs of noma and screen children at risk accordingly. The risk factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe growth failure in the first 6 to 12 months of life",
"     </li>",
"     <li>",
"      Severe malnutrition and poor eating habits",
"     </li>",
"     <li>",
"      Persistent diarrhea",
"     </li>",
"     <li>",
"      Presence of oral mucosal ulcers",
"     </li>",
"     <li>",
"      Malodorous breath",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Proper oral hygiene practices must be taught and promoted. For areas in which toothbrushes and toothpaste are not available, children should be taught to use soft chewing sticks or sponges, under adult supervision. Many of the traditional chewing sticks used in various developing settings are fashioned from plants containing active medicinal properties. Several are from the tea plant family, and may concentrate fluoride from the soil. For very young children, cotton buds may substitute for chewing sticks. Saline solution is helpful for mouth rinsing.",
"   </p>",
"   <p>",
"    As oral ulcers are frequently preceded by antecedent infection, administration of routine immunizations is also a priority. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link\">",
"     \"Standard immunizations for children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sanitation inside and outside of the residential quarters requires careful attention to the following issues:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clean drinking water must be readily available.",
"     </li>",
"     <li>",
"      Human waste must be removed in a timely fashion.",
"     </li>",
"     <li>",
"      Livestock should be segregated from human living quarters.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adequate nutrition in the first three to six months of life is an important priority; breastfeeding should be encouraged. Weaning foods for infants should be prepared under hygienic conditions.",
"   </p>",
"   <p>",
"    Noma occurs almost exclusively in resource limited settings in which the general understanding of the causes of disease may be limited and illness may be interpreted within the framework of superstitious beliefs. Information campaigns are needed at regional and global levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Noma is a severe disfiguring gangrene of the mouth and face that starts as a gingival ulcer and spreads rapidly through the tissues of the mouth and face. It is associated with poverty, malnutrition, and poor sanitation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Noma is a polymicrobial infection associated predominantly with anaerobic organisms, although identifying a specific causative infectious agent can be difficult. Fusobacterium necrophorum is observed most frequently in culture and is suspected to be an important organism for the development of noma. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of noma is highest in sub-Saharan Africa; the disease also occurs in Asia and Latin America. Risk factors include poor oral hygiene, limited access to healthcare services, close residential proximity to livestock, nomadic lifestyle, and high prevalence of infectious diseases including malaria, measles, AIDS, diarrhea, and tuberculosis. Infants and children are particularly susceptible. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of noma is based on clinical manifestations. Suggestive clues include recent or concurrent infection preceding onset of facial swelling and excessive salivation in the setting of malnutrition. In general there are three stages of noma (which may overlap): an acute phase, a gangrenous phase, and a scarring phase. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute treatment consists of antibiotics, wound care, and replacement of needed fluids, electrolytes, and nutrition. We suggest penicillin for antibiotic therapy of noma (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Dosing is as outlined above; the duration is 10 to 14 days. Several months to one year after the acute phase, surgery is performed for correction of trismus and flap creation. Physiotherapy to reduce fibrous scarring should be initiated during the healing phase and continued after surgery. Attention to psychosocial needs is also an important component of treatment, given the cosmetic and functional debilitation associated with noma. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prevention of noma requires a multidisciplinary approach with attention to routine healthcare needs, sanitation, nutrition, and awareness. Measles immunization substantially reduces the risk of noma. Prevention of malaria in pregnant women receiving antenatal care is also important, since placental malaria impairs transplacental transfer of maternal antibodies to the infant. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/1\">",
"      Enwonwu CO. Noma--the ulcer of extreme poverty. N Engl J Med 2006; 354:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/2\">",
"      Enwonwu CO. Epidemiological and biochemical studies of necrotizing ulcerative gingivitis and noma (cancrum oris) in Nigerian children. Arch Oral Biol 1972; 17:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/3\">",
"      Enwonwu CO, Falkler WA Jr, Phillips RS. Noma (cancrum oris). Lancet 2006; 368:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/4\">",
"      Evrard L, Laroque G, Glineur R, Daelemans P. Noma: clinical and evolutive aspect. Acta Stomatol Belg 1996; 93:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/5\">",
"      Tempest MN. Cancrum oris. Br J Surg 1966; 53:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/6\">",
"      Marck KW. A history of noma, the \"Face of Poverty\". Plast Reconstr Surg 2003; 111:1702.",
"     </a>",
"    </li>",
"    <li>",
"     Boot A. Observationes Medicae de Affectibus Omissis. London: Thomas Newcomb, 1649.",
"    </li>",
"    <li>",
"     Tourdes J. Du noma ou du sphacele de la bouche chez les enfants. Thesis. Strasbourg, 1848.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/9\">",
"      Baratti-Mayer D, Pittet B, Montandon D, et al. Noma: an \"infectious\" disease of unknown aetiology. Lancet Infect Dis 2003; 3:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/10\">",
"      Van Damme, PA. Essay noma. Lancet 2006; 368:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/11\">",
"      Leclercq MH. Can dentistry tackle inequality? The challenge of noma. Fdi world 1999; 2:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/12\">",
"      Bourgeois DM, Leclercq MH. The World Health Organization initiative on noma. Oral Dis 1999; 5:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/13\">",
"      Weaver, GH, Tunnicliff, R. Noma. J Infect Dis 1907; 4:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/14\">",
"      Falkler WA Jr, Enwonwu CO, Idigbe EO. Isolation of Fusobacterium necrophorum from cancrum oris (noma). Am J Trop Med Hyg 1999; 60:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/15\">",
"      Falkler WA, Enwonwu CO, Ewell AJ, Idigbe EO. Isolation of fusobacteria from the oral cavities of malnourished Nigerian children living in agricultural and herding villages. Oral Dis 2000; 6:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/16\">",
"      Phillips RS, Enwonwu CO, Falkler WA. Pro- versus anti-inflammatory cytokine profile in African children with acute oro-facial noma (cancrum oris, noma). Eur Cytokine Netw 2005; 16:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/17\">",
"      Enwonwu CO, Falkler WA, Idigbe EO. Oro-facial gangrene (noma/cancrum oris): pathogenetic mechanisms. Crit Rev Oral Biol Med 2000; 11:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/18\">",
"      Hack CE, Aarden LA, Thijs LG. Role of cytokines in sepsis. Adv Immunol 1997; 66:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/19\">",
"      Rotbart HA, Levin MJ, Jones JF, et al. Noma in children with severe combined immunodeficiency. J Pediatr 1986; 109:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/20\">",
"      Falkler WA Jr, Enwonwu CO, Idigbe EO. Microbiological understandings and mysteries of noma (cancrum oris). Oral Dis 1999; 5:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/21\">",
"      Vaidyanathan S, Tullu MS, Lahiri KR, Deshmukh CT. Pseudomonas sepsis with Noma: an association? Indian J Med Sci 2005; 59:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/22\">",
"      Paster BJ, Falkler Jr WA Jr, Enwonwu CO, et al. Prevalent bacterial species and novel phylotypes in advanced noma lesions. J Clin Microbiol 2002; 40:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/23\">",
"      Contreras A, Falkler WA Jr, Enwonwu CO, et al. Human Herpesviridae in acute necrotizing ulcerative gingivitis in children in Nigeria. Oral Microbiol Immunol 1997; 12:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/24\">",
"      Komiska-Kubarska A, Talleyrand D, Bakatubia M. Cutaneous complications during measles in Zairian children: noma-like postmeasles ulcerations. Int J Dermatol 1982; 21:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/25\">",
"      Horning GM. Necotizing gingivostomatitis: NUG to noma. Compend Contin Educ Dent 1996; 17:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/26\">",
"      Barmes DE, Enwonwu CO, Leclercq MH, et al. The need for action against oro-facial gangrene (noma). Trop Med Int Health 1997; 2:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/27\">",
"      Adolph HP, Yugueros P, Woods JE. Noma: a review. Ann Plast Surg 1996; 37:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/28\">",
"      Enwonwu CO, Falkler WA Jr, Idigbe EO, et al. Pathogenesis of cancrum oris (noma): confounding interactions of malnutrition with infection. Am J Trop Med Hyg 1999; 60:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/29\">",
"      Srour ML, Watt B, Phengdy B, et al. Noma in Laos: stigma of severe poverty in rural Asia. Am J Trop Med Hyg 2008; 78:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/30\">",
"      Jim&eacute;nez LM, Duque FL, Baer PN, Jim&eacute;nez SB. Necrotizing ulcerative periodontal diseases in children and young adults in Medell&iacute;n, Colombia, 1965--2000. J Int Acad Periodontol 2005; 7:55.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. World Health Report, 1998, Geneva: WHO, 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/32\">",
"      Bickler SW, Sanno-Duanda B. Epidemiology of paediatric surgical admissions to a government referral hospital in the Gambia. Bull World Health Organ 2000; 78:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/33\">",
"      Bourgeois DM, Diallo B, Frieh C, Leclercq MH. Epidemiology of the incidence of oro-facial noma: a study of cases in Dakar, Senegal, 1981-1993. Am J Trop Med Hyg 1999; 61:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/34\">",
"      Enwonwu CO, Phillips RS, Ferrell CD. Temporal relationship between the occurrence of fresh noma and the timing of linear growth retardation in Nigerian children. Trop Med Int Health 2005; 10:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/35\">",
"      Costini B, Larroque G, Duboscq JC, Montandon D. [Noma or cancrum oris: etiopathogenic and nosologic aspects]. Med Trop (Mars) 1995; 55:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/36\">",
"      Yuca K, Yuca SA, Cankaya H, et al. Report of an infant with noma (cancrum oris). J Dermatol 2004; 31:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/37\">",
"      Chidzonga MM, Mahomva L. Noma (cancrum oris) in human immunodeficiency virus infection and acquired immunodeficiency syndrome (HIV and AIDS): clinical experience in Zimbabwe. J Oral Maxillofac Surg 2008; 66:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/38\">",
"      ADELSBERGER L. Medical observations in Auschwitz concentration camp. Lancet 1946; 1:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/39\">",
"      Dawson J. Cancrum oris. Br Dent J 1945; 79:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/40\">",
"      Idigbe EO, Enwonwu CO, Falkler WA, et al. Living conditions of children at risk for noma: Nigerian experience. Oral Dis 1999; 5:156.",
"     </a>",
"    </li>",
"    <li>",
"     Cunningham-Rundles S, McNeely D, Ananworanich JM. Immune response in malnutrition. In: Immunologic Disorders in Infants and Children, 5th ed, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Elsevier Saunders, Philadelphia 2004. p.761.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/42\">",
"      Cunningham-Rundles S, Lin H, Ho-Lin D, et al. Role of nutrients in the development of neonatal immune response. Nutr Rev 2009; 67 Suppl 2:S152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/43\">",
"      Dylewski ML, Mastro AM, Picciano MF. Maternal selenium nutrition and neonatal immune system development. Biol Neonate 2002; 82:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/44\">",
"      Rahman MJ, Sarker P, Roy SK, et al. Effects of zinc supplementation as adjunct therapy on the systemic immune responses in shigellosis. Am J Clin Nutr 2005; 81:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/45\">",
"      Long KZ, Santos JI, Rosado JL, et al. Impact of vitamin A on selected gastrointestinal pathogen infections and associated diarrheal episodes among children in Mexico City, Mexico. J Infect Dis 2006; 194:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/46\">",
"      Rehan NE, Tafida DS. Low birthweight in Hausa infants. Niger J Paediatr 1981; 8:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/47\">",
"      Ransome-Kuti O. Intra-uterine growth, birthweights and maturity of the African newborn. Acta Paediatr Scand Suppl 1985; 319:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/48\">",
"      McDade TW, Beck MA, Kuzawa C, Adair LS. Prenatal undernutrition, postnatal environments, and antibody response to vaccination in adolescence. Am J Clin Nutr 2001; 74:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/49\">",
"      McDade TW, Beck MA, Kuzawa CW, Adair LS. Prenatal undernutrition and postnatal growth are associated with adolescent thymic function. J Nutr 2001; 131:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/50\">",
"      Moore DC, Elsas PX, Maximiano ES, Elsas MI. Impact of diet on the immunological microenvironment of the pregnant uterus and its relationship to allergic disease in the offspring--a review of the recent literature. Sao Paulo Med J 2006; 124:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/51\">",
"      Rowland RW. Necrotizing ulcerative gingivitis. Ann Periodontol 1999; 4:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/52\">",
"      L&oacute;pez R, Baelum V. Necrotizing ulcerative gingival lesions and clinical attachment loss. Eur J Oral Sci 2004; 112:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/53\">",
"      Enwonwu CO, Phillips RS, Savage KO. Inflammatory cytokine profile and circulating cortisol levels in malnourished children with necrotizing ulcerative gingivitis. Eur Cytokine Netw 2005; 16:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/54\">",
"      Classification and diagnostic criteria for oral lesions in HIV infection. EC-Clearinghouse on Oral Problems Related to HIV Infection and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus. J Oral Pathol Med 1993; 22:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/55\">",
"      Contreras A, Slots J. Herpesviruses in human periodontal disease. J Periodontal Res 2000; 35:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/56\">",
"      Sabiston CB Jr. A review and proposal for the etiology of acute necrotizing gingivitis. J Clin Periodontol 1986; 13:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/57\">",
"      Naniche D. Generalized immunosuppression: individual viruses, intertwined targets. Virology 2000; 275:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/58\">",
"      Phillips RS, Enwonwu CO, Okolo S, Hassan A. Metabolic effects of acute measles in chronically malnourished Nigerian children. J Nutr Biochem 2004; 15:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/59\">",
"      Atabani SF, Byrnes AA, Jaye A, et al. Natural measles causes prolonged suppression of interleukin-12 production. J Infect Dis 2001; 184:1.",
"     </a>",
"    </li>",
"    <li>",
"     Marck, KW. Noma: the face of poverty. MIT-Verlag GmbH, 2003: 53-128.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/61\">",
"      Emslie, RD. Cancrum oris. Dent Pract Dent Rec 1963; 13:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/62\">",
"      Dossetor J, Whittle HC, Greenwood BM. Persistent measles infection in malnourished children. Br Med J 1977; 1:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/63\">",
"      Whittle HC, Smith JS, Kogbe OI, et al. Severe ulcerative herpes of mouth and eye following measles. Trans R Soc Trop Med Hyg 1979; 73:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/64\">",
"      Enwere GC, Ota MO, Obaro SK. The host response in malaria and depression of defence against tuberculosis. Ann Trop Med Parasitol 1999; 93:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/65\">",
"      Lyke KE, Burges R, Cissoko Y, et al. Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls. Infect Immun 2004; 72:5630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/66\">",
"      Shio MT, Tiemi Shio M, Eisenbarth SC, et al. Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases. PLoS Pathog 2009; 5:e1000559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/67\">",
"      Eckstein, A. Noma. Am J Dis Child 1940; 59:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/68\">",
"      Nath S, Jovic G. Cancrum oris: management, incidence, and implications of human immunodeficiency virus in Zambia. Plast Reconstr Surg 1998; 102:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/69\">",
"      Adedoja D, Kabue MM, Sahila P. Cancrum oris in HIV infected children in Lesotho: report of two cases. East Afr Med J 2002; 79:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/70\">",
"      Naidoo S, Chikte UM. Noma (cancrum oris): case report in a 4-year-old HIV-positive South African child. SADJ 2000; 55:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/71\">",
"      Evans LM, Lane H, Jones MK. Cancrum oris in a Caucasian male with Type 2 diabetes mellitus. Diabet Med 2001; 18:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/72\">",
"      Elazary AS, Lador N, Shauer A, et al. Tongue necrosis and pericarditis. Lancet 2004; 363:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/73\">",
"      Kirstil&auml; V, Sew&oacute;n L, Laine J. Periodontal disease in three siblings with familial neutropenia. J Periodontol 1993; 64:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/74\">",
"      Watanabe H, Goseki-Sone M, Iimura T, et al. Molecular diagnosis of hypophosphatasia with severe periodontitis. J Periodontol 1999; 70:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/75\">",
"      Kwong PC, O'Marcaigh AS, Howard R, et al. Oral and genital ulceration: a unique presentation of immunodeficiency in Athabascan-speaking American Indian children with severe combined immunodeficiency. Arch Dermatol 1999; 135:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/76\">",
"      Meyle J, Gonz&aacute;les JR. Influences of systemic diseases on periodontitis in children and adolescents. Periodontol 2000 2001; 26:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/77\">",
"      Limongelli WA, Clark MS, Williams AC. Nomalike lesion in a patient with chronic lymphocytic leukemia. Review of the literature and report of a case. Oral Surg Oral Med Oral Pathol 1976; 41:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/78\">",
"      Berthold P. Noma: a forgotten disease. Dent Clin North Am 2003; 47:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/79\">",
"      Enwonwu CO, Phillips RS, Ibrahim CD, Danfillo IS. Nutrition and oral health in Africa. Int Dent J 2004; 54:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/80\">",
"      Fasola AO, Obiechina AE, Arotiba JT. Unusual presentation of NOMA: a case report. Afr J Med Med Sci 2003; 32:417.",
"     </a>",
"    </li>",
"    <li>",
"     Bos, K, Marck, K. The Surgical treatment of noma. Published by Uitgeverij Belv&eacute;dere/Medidact, Alphen aan den Rijn, The Netherlands, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/82\">",
"      Beisel WR. Nutrition in pediatric HIV infection: setting the research agenda. Nutrition and immune function: overview. J Nutr 1996; 126:2611S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/83\">",
"      Enwonwu CO, Ritchie CS. Nutrition and inflammatory markers. J Am Dent Assoc 2007; 138:70.",
"     </a>",
"    </li>",
"    <li>",
"     Enwonwu CO. Vitamin supplements and oral health. In: Food Constituents and Oral Health. Current Status and Future Prospects, Wilson M (Ed), Woodhead Publishing Ltd., Oxford 2009. p.298.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/85\">",
"      Gruver AL, Sempowski GD. Cytokines, leptin, and stress-induced thymic atrophy. J Leukoc Biol 2008; 84:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/86\">",
"      Savino W, Dardenne M, Velloso LA, Dayse Silva-Barbosa S. The thymus is a common target in malnutrition and infection. Br J Nutr 2007; 98 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/87\">",
"      Slomiany BL, Slomiany A. Role of leptin in modulation of Porphyromonas gingivalis lipopolysaccharide-induced up-regulation of endothelin-1 in salivary gland acinar cells. IUBMB Life 2005; 57:591.",
"     </a>",
"    </li>",
"    <li>",
"     C. Enwonwu, Unpublished data.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/89\">",
"      van Crevel R, Karyadi E, Netea MG, et al. Decreased plasma leptin concentrations in tuberculosis patients are associated with wasting and inflammation. J Clin Endocrinol Metab 2002; 87:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/90\">",
"      Steinberg MW, Turovskaya O, Shaikh RB, et al. A crucial role for HVEM and BTLA in preventing intestinal inflammation. J Exp Med 2008; 205:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/91\">",
"      Cai G, Freeman GJ. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Immunol Rev 2009; 229:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/92\">",
"      Cheung TC. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway. Recent Pat DNA Gene Seq 2009; 3:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/93\">",
"      Biet F, Locht C, Kremer L. Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens. J Mol Med (Berl) 2002; 80:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/94\">",
"      Kashiwamura S, Ueda H, Okamura H. Roles of interleukin-18 in tissue destruction and compensatory reactions. J Immunother 2002; 25 Suppl 1:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/95\">",
"      Eaton AD, Xu D, Garside P. Administration of exogenous interleukin-18 and interleukin-12 prevents the induction of oral tolerance. Immunology 2003; 108:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/96\">",
"      Ishikura T, Kanai T, Uraushihara K, et al. Interleukin-18 overproduction exacerbates the development of colitis with markedly infiltrated macrophages in interleukin-18 transgenic mice. J Gastroenterol Hepatol 2003; 18:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/97\">",
"      Okada H, Sato TA, Katayama A, et al. Comparative analysis of host responses related to immunosuppression between measles patients and vaccine recipients with live attenuated measles vaccines. Arch Virol 2001; 146:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/98\">",
"      Nagamine Y, Hayano M, Kashiwamura S, et al. Involvement of interleukin-18 in severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 2003; 97:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/99\">",
"      Oberholzer A, Steckholzer U, Kurimoto M, et al. Interleukin-18 plasma levels are increased in patients with sepsis compared to severely injured patients. Shock 2001; 16:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/100\">",
"      Brandtzaeg P. Inflammatory bowel disease: clinics and pathology. Do inflammatory bowel disease and periodontal disease have similar immunopathogeneses? Acta Odontol Scand 2001; 59:235.",
"     </a>",
"    </li>",
"    <li>",
"     Mead S. Oral Surgery, The C.V. Mosby Company, St. Louis 1946.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/102\">",
"      Eisele DW, Inglis AF Jr, Richardson MA. Noma and noma neonatorum. Ear Nose Throat J 1990; 69:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/103\">",
"      Juster-Reicher A, Mogilner BM, Levi G, et al. Neonatal noma. Am J Perinatol 1993; 10:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/104\">",
"      Atiyeh BS, Hashim HA, Rubeiz MT, et al. Necrotising infection of the orofacial tissues in neonates (noma neonatorum). Case report. Scand J Plast Reconstr Surg Hand Surg 1998; 32:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/105\">",
"      Parikh TB, Nanavati RN, Udani RH. Noma neonatorum. Indian J Pediatr 2006; 73:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/106\">",
"      Freeman AF, Mancini AJ, Yogev R. Is noma neonatorum a presentation of ecthyma gangrenosum in the newborn? Pediatr Infect Dis J 2002; 21:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/107\">",
"      Johnson PD, Stinear T, Small PL, et al. Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med 2005; 2:e108.",
"     </a>",
"    </li>",
"    <li>",
"     Asiedu K, Scherpbier R, Raviglione M. Buruli ulcer: Mycobacterium ulcerans infection. Geneva: WHO, 2000.",
"    </li>",
"    <li>",
"     World Health Organization. The leishmaniases and leishmania/HIV co-infections. WHO-OMS Fact Sheet, No. 116, Geneva: WHO, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/110\">",
"      Aguiar AM, Enwonwu CO, Pires FR. Noma (cancrum oris) associated with oral myiasis in an adult. Oral Dis 2003; 9:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/111\">",
"      Carvalho RW, Santos TS, Antunes AA, et al. Oral and maxillofacial myiasis associated with epidermoid carcinoma: a case report. J Oral Sci 2008; 50:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/112\">",
"      Bair MJ, Chi H, Wang WS, et al. Necrotizing fasciitis in southeast Taiwan: clinical features, microbiology, and prognosis. Int J Infect Dis 2009; 13:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/113\">",
"      Jain S, Nagpure PS, Singh R, Garg D. Minor trauma triggering cervicofacial necrotizing fasciitis from odontogenic abscess. J Emerg Trauma Shock 2008; 1:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/114\">",
"      Adekeye EO, Ord RA. Cancrum oris: principles of management and reconstructive surgery. J Maxillofac Surg 1983; 11:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/115\">",
"      Pittet B, Jaquinet A, Montandon D. Clinical experience in the treatment of noma sequelae. J Craniofac Surg 2001; 12:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/116\">",
"      Giessler GA, Schmidt AB. Noma: experiences with a microvascular approach under West African conditions. Plast Reconstr Surg 2003; 112:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/117\">",
"      Hartman EH, Van Damme PA, Sauter H, Suominen SH. The use of the pedicled supraclavicular flap in noma reconstructive surgery. J Plast Reconstr Aesthet Surg 2006; 59:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/118\">",
"      Thiery G, Liard O, Duboscq JC. [Treatment of noma]. Med Trop (Mars) 2002; 62:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7129/abstract/119\">",
"      Tassonyi E, Lehmann C, Gunning K, et al. Fiberoptically guided intubation in children with gangrenous stomatitis (noma). Anesthesiology 1990; 73:348.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3037 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_61_7129=[""].join("\n");
var outline_f6_61_7129=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Malnutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Acute necrotizing gingivitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acute phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Gangrenous phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Scarring phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Role of malnutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Inflammatory mediators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Wound care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Fluid, electrolytes and nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Surgical repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3037\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3037|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/56/8066\" title=\"picture 1\">",
"      Noma lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/18/21793\" title=\"picture 2\">",
"      Necrotizing gingivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/51/23345\" title=\"picture 3\">",
"      Necrotizing ulcerative gingivitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11529?source=related_link\">",
"      Enteral nutrition in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=related_link\">",
"      Maintenance fluid therapy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=related_link\">",
"      Oral rehydration therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/60/8137?source=related_link\">",
"      Systemic conditions associated with periodontal disease in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_61_7130="Emergent evaluation of acute respiratory compromise in children";
var content_f6_61_7130=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Emergent evaluation of acute respiratory compromise in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/61/7130/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/61/7130/contributors\">",
"     Debra L Weiner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/61/7130/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/61/7130/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/61/7130/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/61/7130/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/61/7130/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory distress is one of the most common chief complaints for which children seek medical care. It accounts for nearly 10 percent of pediatric emergency department visits and 20 percent of hospitalizations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7130/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Respiratory distress in children, particularly neonates and infants, must be promptly recognized and aggressively treated because they may decompensate quickly. Factors that contribute to rapid respiratory compromise in children include smaller airways, increased metabolic demands, decreased respiratory reserves, and inadequate compensatory mechanisms as compared to adults. Respiratory arrest is the most common cause of cardiac arrest in children and outcomes are poor for patients who develop cardiopulmonary arrest as the result of respiratory deterioration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7130/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The initial assessment and stabilization of children with respiratory and circulatory compromise including airway management techniques, rapid sequence intubation (RSI), causes of respiratory compromise in children, and conditions causing respiratory distress in newborns are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=see_link\">",
"       \"Initial assessment and stabilization of children with respiratory or circulatory compromise\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"       \"Basic airway management in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"       \"Emergent endotracheal intubation in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"       \"Rapid sequence intubation (RSI) in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39113?source=see_link\">",
"       \"Causes of acute respiratory compromise in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31511?source=see_link\">",
"       \"Overview of neonatal respiratory distress: Disorders of transition\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6610635\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of acute respiratory compromise in children is discussed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef61637 \" href=\"UTD.htm?27/39/28285\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39113?source=see_link\">",
"     \"Causes of acute respiratory compromise in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a child with acute respiratory distress includes determining the severity, as well as the underlying cause. Tachypnea and in neonates, infants, and young children, retractions, are hallmarks of respiratory distress. Respiratory distress may manifest as inadequate respiratory effort, most often in those who have tired from attempts to compensate for respiratory compromise, those with underlying neuromuscular disease and those with disordered control of breathing (eg, bronchiolitis, opioid overdose). Tachypnea and decreased respiratory effort can lead to respiratory failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arrest and the child with inadequate respiratory effort is often at more immediate risk.",
"   </p>",
"   <p>",
"    The emergent evaluation of children in respiratory distress must first determine the severity of respiratory distress and the need for emergent intervention. Features of the history and physical examination will ideally localize the source as well as suggest the etiology and direct initial treatment (",
"    <a class=\"graphic graphic_table graphicRef79944 \" href=\"UTD.htm?25/23/25980\">",
"     table 2",
"    </a>",
"    ). Ancillary studies can then be performed as indicated to confirm the diagnosis and guide management (",
"    <a class=\"graphic graphic_table graphicRef82210 \" href=\"UTD.htm?39/25/40349\">",
"     table 3",
"    </a>",
"    ). The clinical features and evaluation of specific conditions that cause acute respiratory distress in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39113?source=see_link\">",
"     \"Causes of acute respiratory compromise in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of etiology, the initial management of respiratory distress in children requires immediate evaluation and supportive care of airway, breathing, and circulation. For some conditions, specific interventions (ie, bronchodilator therapy for asthma or decompression of a pneumothorax) may rapidly relieve symptoms. With prompt aggressive treatment of respiratory distress and its underlying cause, most children with respiratory distress recover uneventfully.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Initial rapid assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pediatric assessment triangle (PAT) provides a quick evaluation of appearance, breathing, and circulation for acutely ill or injured children that should identify conditions that require immediate intervention. The PAT is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=see_link&amp;anchor=H3#H3\">",
"     \"Initial assessment and stabilization of children with respiratory or circulatory compromise\", section on 'Pediatric assessment triangle'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Features of the PAT that are specific to children with acute respiratory compromise include (see",
"    <a class=\"local\" href=\"#H24\">",
"     'General observation'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Appearance",
"      </strong>",
"      &ndash; Restlessness, anxiety, or combativeness suggest hypoxia. Somnolence or lethargy may be the result of severe hypoxia, hypercarbia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      respiratory fatigue.",
"     </li>",
"     <li>",
"      <strong>",
"       Breathing",
"      </strong>",
"      &ndash; The initial response to respiratory compromise is usually tachypnea. Abnormal airway sounds (eg, stridor, wheezing), increased accessory muscle use, and positioning to maximize airway opening (eg, &ldquo;sniffing&rdquo; position, &ldquo;tripod&rdquo; position) are other indicators of respiratory compromise. As respiratory compromise progresses, respiratory rate often decreases and the pattern of respirations becomes irregular. These are ominous signs. Without intervention, respiratory arrest quickly ensues.",
"     </li>",
"     <li>",
"      <strong>",
"       Circulatory status",
"      </strong>",
"      &ndash; Pallor, ashen color, and cyanosis are concerning findings that may indicate hypoxemia, but may also be observed in patients with shock.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Conditions that require immediate, life-saving interventions include (",
"    <a class=\"graphic graphic_table graphicRef57278 \" href=\"UTD.htm?2/46/2797\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete or rapidly progressing partial upper airway obstruction",
"     </li>",
"     <li>",
"      Tension pneumothorax",
"     </li>",
"     <li>",
"      Cardiac tamponade",
"     </li>",
"     <li>",
"      Respiratory failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Throughout this evaluation, every reasonable effort must be made to keep the child calm and comfortable, since anxiety and crying can substantially increase the work of breathing in young children by decreasing upper airway diameter and increasing metabolic demand for oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7130/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed history should be obtained once the child's condition is stabilized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=see_link&amp;anchor=H15#H15\">",
"     \"Initial assessment and stabilization of children with respiratory or circulatory compromise\", section on 'Initial stabilization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Helpful historical information includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Trauma",
"      </strong>",
"      &ndash; A history of recent trauma suggests specific diagnoses, such as pneumothorax, pulmonary contusion, flail chest, cardiac tamponade, abdominal or CNS injury.",
"     </li>",
"     <li>",
"      <strong>",
"       Change in voice",
"      </strong>",
"      &ndash; Many children with acute upper airway pathology will have a change in voice (either muffled or hoarse). In comparison, those with lower airway processes have a normal voice.",
"     </li>",
"     <li>",
"      <strong>",
"       Onset and duration of symptoms",
"      </strong>",
"      &ndash; The abrupt onset of gagging or choking suggests upper airway conditions, such as an aspirated foreign body, allergy, or irritant exposure. A child who suddenly complains of chest pain may have a pneumothorax. In contrast, an infant who gradually develops tachypnea and retractions may have asthma, bronchopulmonary infection, or heart failure.",
"     </li>",
"     <li>",
"      <strong>",
"       Associated symptoms",
"      </strong>",
"      &ndash; Fever suggests an infectious etiology. Fever itself can result in an increase in respiratory rate of three to seven breaths per minute per degree centigrade above normal [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7130/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. A child with tachypnea without fever, URI symptoms, or cough may be compensating for a metabolic acidosis. A complaint of abdominal pain may indicate a gastrointestinal process (ie, appendicitis or bowel obstruction), diaphragmatic irritation from a pneumonic condition (as can occur with basilar pneumonia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pleural effusion), or a metabolic abnormally (ie, ketoacidosis from diabetes).",
"     </li>",
"     <li>",
"      <strong>",
"       Exposures",
"      </strong>",
"      &ndash; Exposure to specific infections, toxins (including medications, substances of abuse, biologic, chemical or nuclear agents), or allergens may suggest an etiology for respiratory distress.",
"     </li>",
"     <li>",
"      <strong>",
"       Previous episodes",
"      </strong>",
"      &ndash; Information regarding previous episodes of respiratory distress, including treatments that have been used and their effect, may guide interventions. As an example, a young child, who has not been diagnosed with asthma, may have had episodes of wheezing that responded to bronchodilators.",
"     </li>",
"     <li>",
"      <strong>",
"       Underlying medical conditions",
"      </strong>",
"      &ndash; Respiratory distress may be an acute sign of a process associated with a specific chronic medical condition (ie, acute chest syndrome in a child with sickle cell disease) or a complication of a chronic condition (ie, pneumothorax in a patient with asthma). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39113?source=see_link&amp;anchor=H13169188#H13169188\">",
"       \"Causes of acute respiratory compromise in children\", section on 'Acute on chronic diseases'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Family history",
"      </strong>",
"      &ndash; Family history of inheritable conditions (including asthma, cardiac disease, diabetes mellitus) may give clues to possible undiagnosed etiologies of respiratory distress.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial physical examination of the child with severe respiratory distress should be completed rapidly, focusing on the respiratory and cardiovascular systems, but recognizing that other organ system processes may be the etiology of respiratory distress [",
"    <a class=\"abstract\" href=\"UTD.htm?6/61/7130/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After rapid assessment of airway, breathing and circulation, vital signs, including pulse oximetry, and actual or estimated weight, should be obtained. Side port capnography, if available, may also be helpful in detecting hypercarbia. Once the child is stabilized, the clinician should perform a complete physical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     General observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following observations suggest severe respiratory compromise:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mental status",
"      </strong>",
"      &ndash; Restlessness, anxiety, or combativeness suggest hypoxia. Somnolence or lethargy may be the result of severe hypoxia, hypercarbia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      respiratory fatigue.",
"     </li>",
"     <li>",
"      <strong>",
"       Position of comfort",
"      </strong>",
"      &ndash; To maximize airway patency, a child with upper airway obstruction may sit upright and assume the \"sniffing position\" (neck flexed, head mildly extended) to align the airway axes and improve airflow (",
"      <a class=\"graphic graphic_picture graphicRef76538 \" href=\"UTD.htm?8/0/8197\">",
"       picture 1",
"      </a>",
"      ). With lower airway disease, the child may assume a &ldquo;tripod position&rdquo; in which the child is sitting up and leaning forward on outstretched hands.",
"     </li>",
"     <li>",
"      <strong>",
"       Cyanosis",
"      </strong>",
"      &ndash; Cyanosis is generally a late finding in children with hypoxemia. It is seen most often in those who have low cardiac output in addition to low arterial oxygen saturation. Severely anemic patients (Hemoglobin &lt;5",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      may not manifest cyanosis despite severe hypoxia.",
"     </li>",
"     <li>",
"      <strong>",
"       Drooling, dysphagia",
"      </strong>",
"      &ndash; Inability to handle secretions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      swallow are signs of oropharyngeal or laryngotracheal obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1164272\">",
"    <span class=\"h3\">",
"     Vital signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory rate, heart rate, blood pressure, and oxygen saturation give clues to the presence and etiology of respiratory distress.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Respiratory rate",
"      </strong>",
"      &ndash; Normal respiratory rate varies by age (",
"      <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"       table 5",
"      </a>",
"      ). Tachypnea is one of the most important findings in children with respiratory disease. Tachypnea may also occur due to fever, activity, crying, cardiac disease, and metabolic acidosis. For example, increases in respiratory rates of three to seven breaths per minute per degree Celsius above baseline have been reported in response to fever [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7130/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. For children &lt;12 months of age the compensatory increase may be as high as 7 to 11 breaths per minute per degree Celsius above baseline (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39113?source=see_link&amp;anchor=H13169095#H13169095\">",
"       \"Causes of acute respiratory compromise in children\", section on 'Causes'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Apnea and bradypnea in neonates and infants with respiratory disease is usually the result of respiratory muscle fatigue. In neonates, particularly premature neonates central immaturity is a common cause of apnea. In young infants, apnea may be the initial manifestation of bronchiolitis or pertussis. Other causes of apnea in infants and young children include head trauma (eg, abusive head trauma), severe metabolic acidosis, and poisoning.",
"     </li>",
"     <li>",
"      <strong>",
"       Heart rate",
"      </strong>",
"      &ndash; Tachycardia due to increased sympathetic tone is commonly present in children with respiratory distress. With prolonged respiratory compromise, tachycardia may reflect dehydration due, at least in part, to tachypnea. Bradycardia in a hypoxic child is a late and ominous sign that often signals impending cardiopulmonary arrest.",
"     </li>",
"     <li>",
"      <strong>",
"       Pulsus paradoxus",
"      </strong>",
"      &ndash; Pulsus paradoxus, an exaggeration (greater than 10 mmHg) of the normal decrease in blood pressure during inspiration, correlates with degree of airway obstruction. Pulsus paradoxus occurs as the result of accentuated swings in pleural pressure between inspiration and expiration. It also occurs when hyperinflation of the lungs limits inspiratory filling, and therefore left ventricular stroke volume of the heart and in patients with cardiac tamponade. Although not specific, the presence of pulsus paradoxus is an important indicator that severe respiratory distress or impingement on cardiac output is occurring. Accurate measurement of pulsus paradoxus is often difficult in young children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link&amp;anchor=H16#H16\">",
"       \"Cardiac tamponade\", section on 'Pulsus paradoxus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Oxygen saturation",
"      </strong>",
"      &ndash; A resting room air oxygen saturation &le;97 percent by pulse oximetry is abnormal in full-term infants and children although this measurement should not be considered in isolation in any individual patient [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7130/abstract/10\">",
"       10",
"      </a>",
"      ]. Values &le;90 percent indicate significant tissue hypoxia. Hypoxia may also be present in patients with oxygen saturations between 90 and 95 percent who are also tachypneic.",
"      <br/>",
"      <br/>",
"      Oxygen saturation measurement may be adversely affected by the following factors (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=see_link\">",
"       \"Pulse oximetry\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=see_link&amp;anchor=H7#H7\">",
"       \"Pulse oximetry\", section on 'Patient-related errors'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Probe removal by the patient, improper placement, or motion artifact",
"     </li>",
"     <li>",
"      Poor peripheral perfusion",
"     </li>",
"     <li>",
"      Severe anemia (hemoglobin &lt;5",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"     </li>",
"     <li>",
"      Hypothermia",
"     </li>",
"     <li>",
"      Venous congestion",
"     </li>",
"     <li>",
"      Fingernail polish",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3777178\">",
"    <span class=\"h3\">",
"     Breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed assessment of breathing is imperative in children with respiratory compromise and includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Inspection",
"      </strong>",
"      &ndash; Some of the most valuable information regarding the severity and etiology of respiratory distress is obtained by careful observation of the pediatric patient. The following should be noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Respiratory pattern",
"      </strong>",
"      &ndash; The pattern of respiration may provide a clue to the etiology of respiratory distress:",
"      <br/>",
"      <br/>",
"      Rapid, shallow breathing with prolonged exhalation is typically seen with air trapping, as occurs with asthma or bronchiolitis. It may also result from chest or abdominal pain or chest wall dysfunction.",
"      <br/>",
"      <br/>",
"      Kussmaul respirations (deep, regular, sighing breaths that may be rapid, slow, or normal in rate) suggest metabolic acidosis, particularly diabetic ketoacidosis.",
"      <br/>",
"      <br/>",
"      Cheyne-Stokes respirations (respirations with increasing then decreasing depth and rate alternating with periods of apnea) occur as the result of central nervous system immaturity in otherwise normal neonates, particularly during sleep. This pattern can also be seen in neonates, infants, and children with inadequate cerebral perfusion, brain injury, increased intracranial pressure, and central narcotic depression.",
"      <br/>",
"      <br/>",
"      Ataxic respirations (breaths of irregular depth interrupted irregularly by periods of apnea) suggest central nervous system infection, injury, or drug-induced depression.",
"      <br/>",
"      <br/>",
"      Thoracoabdominal dissociation or paradoxical breathing (chest collapses on inspiration, while abdomen protrudes) is a sign of respiratory fatigue or muscle weakness.",
"     </li>",
"     <li>",
"      <strong>",
"       Tracheal deviation",
"      </strong>",
"      &ndash; Tracheal deviation is a key finding in tension pneumothorax. Air accumulation displaces the trachea to the side opposite the pneumothorax. Tracheal deviation may also be seen in patients with unilateral pulmonary emphysema, unilateral effusion, or thoracic mass.",
"     </li>",
"     <li>",
"      <strong>",
"       Accessory muscle use",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Accessory muscle use is an important indicator of respiratory distress in infants and children and may cause several different findings:",
"      <br/>",
"      <br/>",
"      Nasal flaring, which describes exaggerated opening and closing of the nostrils, is a subtle form of severe accessory muscle use that is commonly seen in infants.",
"      <br/>",
"      <br/>",
"      Head bobbing refers to extension of the head and neck during inhalation and falling forward of the head during exhalation and also suggests severe respiratory distress, especially in infants.",
"      <br/>",
"      <br/>",
"      Retractions of the muscles of the chest wall result from high negative intrathoracic pressure generated by increased respiratory effort. Supraclavicular and suprasternal retractions are usually indicative of upper airway obstruction, but may be seen with severe lower airway processes. Intracostal and subcostal retractions are indicators of lower airway obstruction but can be seen in severe upper airway obstruction. Mild retractions may be normal in neonates and infants. Severe retractions of more than one muscle group indicate significant distress [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7130/abstract/11\">",
"       11",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Abdominal breathing, characterized by thoracoabdominal dissociation, in which the chest collapses and the abdomen protrudes on inspiration, is a sign of respiratory muscle fatigue seen in young children or in patients with poor muscle tone.",
"     </li>",
"     <li>",
"      <strong>",
"       Chest wall movement",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Chest excursion with inspiration is an indication of tidal volume. Poor movement indicates inadequate ventilation. In addition, asymmetric movement suggests a localized process, such as pneumothorax or flail chest.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Abnormal sounds",
"      </strong>",
"      &mdash; Abnormal sounds can often be appreciated without auscultation. These include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Stertor",
"      </strong>",
"      &ndash; Stertor, snoring, due to nasal obstruction, is most commonly caused by nasal congestion, tonsil",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      adenoid hypertrophy, or neuromuscular weakness.",
"     </li>",
"     <li>",
"      <strong>",
"       Gurgling",
"      </strong>",
"      &ndash; Gurgling, which may be inspiratory",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      expiratory is due to secretions in the posterior oropharynx, trachea,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bronchi.",
"     </li>",
"     <li>",
"      <strong>",
"       Stridor",
"      </strong>",
"      &ndash; Stridor is a type of inspiratory wheeze that localizes respiratory distress to the upper airway.",
"     </li>",
"     <li>",
"      <strong>",
"       Change in voice",
"      </strong>",
"      &ndash; An abnormal voice (most commonly hoarse or muffled) suggests upper airway obstruction.",
"     </li>",
"     <li>",
"      <strong>",
"       Aphonia",
"      </strong>",
"      &ndash; Aphonia results from complete upper airway obstruction or vocal cord dysfunction.",
"     </li>",
"     <li>",
"      <strong>",
"       Cough",
"      </strong>",
"      &ndash; Acute cough may be due to infection, inflammation, bronchospasm",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      obstruction. Quality and duration of cough provide clues to etiology. A barky cough indicates subglottic tracheal obstruction, most commonly due to croup. A staccato cough suggests pneumonia caused by Chlamydia or Mycoplasma. A dry, tight, cough may occur in patients with wheezing due to asthma or bronchiolitis, whereas a loose wet cough may indicate tracheal secretions or bacterial pneumonia. Causes of chronic cough in children are discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28088?source=see_link\">",
"       \"Causes of chronic cough in children\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Wheezes",
"      </strong>",
"      &ndash; Wheezes can sometimes be heard without a stethoscope in patients with status asthmaticus, bronchiolitis or if inspiratory, patients with croup.",
"     </li>",
"     <li>",
"      <strong>",
"       Grunting",
"      </strong>",
"      &ndash; Grunting is an end expiratory sound that occurs as the result of exhalation against a partially closed glottis. It slows expiratory flow, increasing lung volume and alveolar pressures [",
"      <a class=\"abstract\" href=\"UTD.htm?6/61/7130/abstract/9\">",
"       9",
"      </a>",
"      ]. Grunting is typically a sign of moderate to severe respiratory distress that occurs in young infants and children with lower airway disease, such as pneumonia, atelectasis, or pulmonary edema. It may also be heard in children with abdominal processes that limit respiratory effort due to pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abdominal distension (eg, intraabdominal injury, perforated viscous).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Auscultation",
"      </strong>",
"      &ndash; Auscultation provides important information regarding the etiology of respiratory distress and localization of the underlying condition. Every effort should be made to quiet the infant or child during auscultation.",
"      <br/>",
"      <br/>",
"      The presence of the following should be noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Wheezes",
"      </strong>",
"      &ndash; Diffuse expiratory wheezes are a sign of lower airway intrathoracic obstruction typically caused by asthma or bronchiolitis. They are musical in tone with higher pitched wheezes indicative of more severe obstruction. Unilateral wheezes may be appreciated with a foreign body in the lower airway. Inspiratory wheezes indicate an upper airway extrathoracic obstruction or a severe fixed intrathoracic obstruction, and are most commonly due to laryngeal edema or a foreign body. In severe cases, wheezes can be appreciated without a stethoscope. However, if asthma is so severe that air movement is poor, wheezes may not be present.",
"     </li>",
"     <li>",
"      <strong>",
"       Prolonged expiratory phase",
"      </strong>",
"      &ndash; A prolonged expiratory phase is a reliable sign of obstructed lower airways that can occur with or without wheezes. In the normal respiratory cycle, inspiration is longer than expiration (normal 3:1 for vesicular sounds, 2:1 bronchovesicular, 1:1 tracheal) with the exception of bronchial sounds for which expiration is slightly longer than inspiration. An expiratory phase that is longer than the inspiratory phase suggests obstruction even in the absence of wheezes.",
"     </li>",
"     <li>",
"      <strong>",
"       Upper airway sounds",
"      </strong>",
"      &ndash; Transmitted upper airway sounds are noted commonly in small children. Noises generated in the upper airway (ie, stertor due to nasal obstruction from congestion) are easily heard homogeneously throughout the lung fields, particularly in neonates and infants because of their small size and thin-walled chest. Inspiratory stridor suggests significant narrowing of the airway above the sternal notch.",
"     </li>",
"     <li>",
"      <strong>",
"       Decreased breath sounds",
"      </strong>",
"      &ndash; Decreased breath sounds noted in localized lung fields are the result of lower airways processes, such as pneumonia, pleural effusion, or atelectasis.",
"     </li>",
"     <li>",
"      <strong>",
"       Rales",
"      </strong>",
"      &ndash; Also known as crackles are typically high-pitched sounds heard during inspiration, often late phase, as deflated small airways reinflate. Inspiratory rales are heard in conditions, such as bronchiolitis, pneumonia or pulmonary edema. They may be particularly audible with the deep inspiration of crying. Rales may also be heard during expiration due to intrathoracic obstruction caused by conditions, such as bronchiolitis, asthma, cystic fibrosis and lower airway foreign body and are more pronounced by having infants and children exhale forcefully as if blowing out candles. Rales that clear with coughing are usually not significant.",
"     </li>",
"     <li>",
"      <strong>",
"       Rhonchi",
"      </strong>",
"      &ndash; Also referred to as coarse rales, rhonchi are harsh, low-pitched sounds, wet or dry, heard in inspiration, or expiration due to airway obstruction from secretions, edema, or inflammation. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Bronchophony, pectoriloquy, and egophony",
"      </strong>",
"      &ndash; With bronchophony spoken diphthong syllables that start as one vowel and change to another, such as &ldquo;toy boat&rdquo; or &ldquo;blue balloon&rdquo;, are heard more distinctly over an area of consolidation. With pectoriloquy, the syllable, when whispered, is louder in the area of consolidation. Egophony is a change in sound, such as &ldquo;ee&rdquo; to &ldquo;ay&rdquo; with consolidation. These findings may be helpful in older, cooperative children but are less reliable findings in children younger than five years of age because breath sounds are easily transmitted throughout the chest.",
"     </li>",
"     <li>",
"      <strong>",
"       Pleural rub",
"      </strong>",
"      &ndash; A pleural rub is a low-pitched, grating sound heard with inspiration and expiration caused by inflammation of pleural surfaces with friction as they move against each other during respiration. A pleural rub may be associated with pneumonia or a lung abscess.",
"     </li>",
"     <li>",
"      <strong>",
"       Pericardial rub",
"      </strong>",
"      &ndash; A pericardial rub occurs when inflamed parietal and visceral pericardial surfaces rub against each other. It is heard best between the apex and the sternum. It may be difficult to distinguish from pleural rub.",
"      <br/>",
"      <br/>",
"      Hamman&rsquo;s crunch or sign describes pericardial crackles heard near the heart in synchrony with the heart beat. This finding results from the heart beating against air-filled tissues in patients with pneumomediastinum, pneumopericardium, tracheobronchial injury, or left sided pneumothorax.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Palpation and percussion",
"      </strong>",
"      &ndash; The following signs elicited by palpation and percussion of the chest indicate a respiratory tract etiology for respiratory distress:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Crepitus",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Subcutaneous air due to an air leak (eg, pneumothorax) causes crepitus, a crunching sensation beneath the skin during palpation over the neck and chest.",
"     </li>",
"     <li>",
"      <strong>",
"       Tactile rhonchi",
"      </strong>",
"      &ndash; Vibratory rhonchi palpated over the large airways suggests the presence of fluid in the airway.",
"     </li>",
"     <li>",
"      <strong>",
"       Fremitus",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Fremitus is palpable vibration of the thoracic wall. Tactile fremitus, vibration elicited by speaking diphthong phrases, such as &ldquo;toy boat&rdquo; or &ldquo;blue balloons&rdquo;, is focally increased over an area of consolidation and decreased over pneumothorax or pleural effusion.",
"     </li>",
"     <li>",
"      <strong>",
"       Percussion",
"      </strong>",
"      &ndash; Hyperresonance with percussion of the chest wall may indicate air trapping in patients with asthma or bronchiolitis or air leak in patients with pneumothorax.",
"      <br/>",
"      <br/>",
"      Dullness with percussion suggests an area of consolidation (eg, atelectasis, bronchopneumonia, pleural effusion).",
"      <br/>",
"      <br/>",
"      Level of lung percussion during full inspiration and full expiration, used to assess diaphragmatic movement, suggests air trapping when diaphragm elevation is decreased during expiration and intraabdominal distention, or organomegaly when downward movement of the diaphragm is decreased during inspiration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Other organ systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings in other organ systems can indicate a etiology for the child's respiratory compromise other than pulmonary disease (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39113?source=see_link&amp;anchor=H13169151#H13169151\">",
"     \"Causes of acute respiratory compromise in children\", section on 'Other conditions'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Central nervous system",
"      </strong>",
"      &ndash; Altered mental status and abnormal respiratory rate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pattern may accompany a variety of pulmonary conditions. It can also indicate serious central nervous system (CNS) disease, such as febrile CNS infection trauma, toxic ingestion, hyperammonemia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      seizure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28136?source=see_link&amp;anchor=H6#H6\">",
"       \"Evaluation of stupor and coma in children\", section on 'Etiologies'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link&amp;anchor=H8#H8\">",
"       \"Approach to the child with occult toxic exposure\", section on 'Altered mental status'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Heart",
"      </strong>",
"      &ndash; Respiratory distress in a patient with signs of cardiac compromise, such as a gallop murmur, jugular venous distention, or hepatomegaly, may be due to heart failure or cardiogenic shock. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=see_link&amp;anchor=H12#H12\">",
"       \"Initial evaluation of shock in children\", section on 'Circulation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Gastrointestinal tract",
"      </strong>",
"      &ndash; Rapid, shallow respirations",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      grunting in a child is a concerning finding for severe respiratory compromise. If no pulmonary etiology is apparent, then the clinician should evaluate for an intraabdominal process suggested by abdominal tenderness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      distension, including solid organ or hollow viscous injury or surgical process with or without peritonitis.",
"     </li>",
"     <li>",
"      <strong>",
"       Endocrine",
"      </strong>",
"      &ndash; Rapid, deep respirations in a child who has no evident pulmonary condition may be caused by severe metabolic acidosis in a child with diabetic ketoacidosis. Additional clinical findings include polydypsia, polyuria, weight loss, dehydration, and abdominal pain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical features and diagnosis of diabetic ketoacidosis in children\", section on 'Signs and symptoms'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Metabolic",
"      </strong>",
"      &ndash; Metabolic acidosis caused by an inborn error of metabolism or toxic ingestion (eg, methanol, ethylene glycol, salicylates) may cause significant tachypnea or Kussmaul breathing or both. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link&amp;anchor=H4#H4\">",
"       \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=see_link&amp;anchor=H4#H4\">",
"       \"Methanol and ethylene glycol poisoning\", section on 'Clinical features of overdose'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Allergy",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Urticaria, facial swelling,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      oropharyngeal edema suggest an anaphylactic reaction in patients with respiratory distress and stridor or wheezing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link&amp;anchor=H7#H7\">",
"       \"Anaphylaxis: Rapid recognition and treatment\", section on 'Symptoms and signs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical evaluation is often all that is required to diagnose the etiology of respiratory distress. Diagnostic tests should be used selectively based upon clinical findings (",
"    <a class=\"graphic graphic_table graphicRef82210 \" href=\"UTD.htm?39/25/40349\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Bedside evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with respiratory distress should have hemoglobin oxygen saturation measured with pulse oximetry as early as possible during their evaluations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=see_link\">",
"     \"Pulse oximetry\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    End-tidal or transcutaneous CO2 measurement, if available, can assess ventilation in patients with findings of respiratory compromise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=see_link&amp;anchor=H10#H10\">",
"     \"Initial assessment and stabilization of children with respiratory or circulatory compromise\", section on 'Ancillary studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1164505\">",
"    <span class=\"h3\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of laboratory testing depends upon the severity of respiratory distress and the ability to diagnose the underlying etiology based upon clinical findings alone. For example, patients with moderate respiratory distress from an obvious etiology that responds to interventions (eg, children with status asthmaticus who improve after receiving bronchodilators and corticosteroids) usually do not require specific testing. &nbsp;",
"   </p>",
"   <p>",
"    Patients who have findings of severe respiratory distress warrant measurement of an arterial blood gas to assess ventilation and more accurately determine oxygenation. These measurements can be correlated with continuous noninvasive monitoring with pulse oximetry and end-tidal carbon dioxide measurement and can help determine the need for further airway management, such as endotracheal intubation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=see_link&amp;anchor=H14#H14\">",
"     \"Initial assessment and stabilization of children with respiratory or circulatory compromise\", section on 'Arterial blood gas/venous blood gas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other studies may be necessary depending upon clinical findings. For example, a complete blood count with differential in patients with suspected infection or anemia; rapid blood glucose, electrolytes, and blood gas in a patient with suspected diabetic ketoacidosis; blood, urine, and cerebrospinal fluid cultures in a child with fever and altered mental status (",
"    <a class=\"graphic graphic_table graphicRef82210 \" href=\"UTD.htm?39/25/40349\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;While not all etiologies of respiratory distress require imaging for identification, selective imaging may establish the etiology for a patient's respiratory distress (",
"    <a class=\"graphic graphic_table graphicRef82210 \" href=\"UTD.htm?39/25/40349\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain radiographs &ndash; Plain radiographs are frequently helpful in confirming clinical diagnoses:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A soft tissue radiograph of the lateral neck may identify a retropharyngeal abscess, tracheitis, epiglottitis, croup, or radiopaque foreign body in a child with upper airway obstruction.",
"     </li>",
"     <li>",
"      AP and lateral chest radiographs can localize and identify pulmonary and cardiac etiologies based on findings, such as pulmonary consolidation, atelectasis, pleural",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pericardial fluid, and air leak.",
"     </li>",
"     <li>",
"      Lateral decubitus or inspiratory and forced expiratory chest radiographs, or fluoroscopy may be useful for identifying a foreign body aspiration.",
"     </li>",
"     <li>",
"      KUB and upright abdominal radiographs may provide clues to an intraabdominal etiology of respiratory distress.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Echocardiogram may be indicated in patients with cardiac compromise to diagnose a structural",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      functional cardiac abnormality. &nbsp;",
"     </li>",
"     <li>",
"      Ultrasound may be useful for diagnosis of pericardial and intraabdominal fluid or pneumothorax and to access cardiac function.",
"     </li>",
"     <li>",
"      Computed tomography (CT) of the chest is useful to diagnosis intra- and extrathoracic structural abnormalities, masses and vascular processes of the pulmonary and cardiac systems and the thoracic chest wall.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory distress must be promptly recognized and treated. Delay may result in respiratory failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiopulmonary arrest. Airway management in patients with signs of impending respiratory failure should be initiated prior to full evaluation. Diagnosis based upon history, signs and symptoms of illness, underlying conditions and evaluation should be established as expeditiously as possible to guide definitive treatment (",
"    <a class=\"graphic graphic_algorithm graphicRef66401 \" href=\"UTD.htm?39/24/40322\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39113?source=see_link&amp;anchor=H13169102#H13169102\">",
"     \"Causes of acute respiratory compromise in children\", section on 'Immediately life-threatening conditions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=see_link\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1165119\">",
"    <span class=\"h2\">",
"     Upper airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with upper airway symptoms, such as choking, gagging, or changes in voice,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stridor, are likely to have an upper airway obstruction, such as a foreign body, as the etiology of their distress. Further evaluation and treatment depends on whether the obstruction is complete or partial. The approach is shown in the algorithms and discussed in more detail separately (",
"    <a class=\"graphic graphic_algorithm graphicRef55990 \" href=\"UTD.htm?22/48/23296\">",
"     algorithm 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef54996 \" href=\"UTD.htm?9/37/9810\">",
"     algorithm 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=see_link\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1165126\">",
"    <span class=\"h2\">",
"     Impending respiratory arrest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with impending respiratory arrest warrant rapid interventions to stabilize airway and breathing depending upon the underlying etiology as follows: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Respiratory failure",
"      </strong>",
"      &ndash; Children with lower respiratory tract disease or heart failure, such as neonates with congenital heart disease, young infants with severe bronchiolitis, older children with pneumonia, may present in respiratory failure. Typical signs of impending respiratory arrest include a slow or irregular respiratory rate and poor respiratory effort. Supplemental oxygen and assisted ventilation must be promptly provided and the airway secured by rapid sequence intubation (",
"      <a class=\"graphic graphic_table graphicRef51456 \" href=\"UTD.htm?17/26/17837\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"       \"Basic airway management in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"       \"Rapid sequence intubation (RSI) in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"       \"Emergent endotracheal intubation in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Tension pneumothorax, bilateral pneumothoraces",
"      </strong>",
"      &ndash; Patients with tension pneumothorax typically have decreased breath sounds on the affected side. Note that the rare patient with bilateral pneumothoraces may have symmetric findings on examination. Tension pneumothorax or bilateral pneumothoraces may be rapidly fatal and require immediate decompression based upon clinical diagnosis. Needle thoracostomy should be performed and followed by chest tube placement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39113?source=see_link&amp;anchor=H13169123#H13169123\">",
"       \"Causes of acute respiratory compromise in children\", section on 'Tension pneumothorax'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link\">",
"       \"Placement and management of thoracostomy tubes\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Other findings include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Chest hyperexpansion on the affected side",
"     </li>",
"     <li>",
"      Tracheal deviation with shift of trachea to contralateral side which is not reliably seen in young children",
"     </li>",
"     <li>",
"      Cardiovascular compromise progressing to shock.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cardiac tamponade",
"      </strong>",
"      &ndash; Pericardiocentesis must be performed emergently for patients with cardiac tamponade. An echocardiogram should be performed, whenever possible, to confirm the diagnosis and guide the procedure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=see_link\">",
"       \"Emergency pericardiocentesis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39113?source=see_link&amp;anchor=H18957925#H18957925\">",
"       \"Causes of acute respiratory compromise in children\", section on 'Cardiac tamponade'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Flail chest",
"      </strong>",
"      &ndash; Children with impending respiratory arrest as the result of a flail chest require positive pressure ventilation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12807?source=see_link&amp;anchor=H8#H8\">",
"       \"Chest wall injuries in children\", section on 'Flail chest'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39113?source=see_link&amp;anchor=H13169144#H13169144\">",
"       \"Causes of acute respiratory compromise in children\", section on 'Other traumatic conditions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Massive hemorrhage",
"      </strong>",
"      &ndash; Massive hemorrhage can cause respiratory distress as the result of decreased oxygen carrying capacity and shock. Airway management should be performed with cervical spine immobilization when cervical spine injury cannot be ruled out. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"       \"Emergent endotracheal intubation in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Central nervous system injury",
"      </strong>",
"      &ndash; Central nervous system injury may result in respiratory depression that leads to respiratory arrest. Airway management should be performed with cervical spine immobilization when cervical spine injury cannot be ruled out. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link&amp;anchor=H14#H14\">",
"       \"Initial approach to severe traumatic brain injury in children\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Other respiratory distress",
"    </span>",
"    &nbsp;&mdash;&nbsp;The algorithm provides a diagnostic approach to the causes of acute respiratory distress in children caused by lower airway disease and based upon physical examination (",
"    <a class=\"graphic graphic_algorithm graphicRef66401 \" href=\"UTD.htm?39/24/40322\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6450456\">",
"    <span class=\"h3\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injured children who do not have upper airway symptoms may have sustained a thoracic injury, resulting in pneumothorax or hemothorax, flail chest, pulmonary contusion, or pericardial effusion that compromises cardiopulmonary function. Some, but not all patients will also have signs of chest wall injury, such as abrasions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bruising. Young children may have serious thoracic injury without external signs of trauma. Those with air leak may have chest wall crepitus. Respiratory distress can also develop as the result of splinting from pain associated with thoracic or abdominal injuries. Central nervous system injury or massive hemorrhage may also cause respiratory depression. Frequently, children with respiratory distress after a traumatic injury have multisystem trauma and warrant evaluation and treatment according to advanced trauma life support guidelines (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H8#H8\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Initial approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6450480\">",
"    <span class=\"h3\">",
"     No trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of atraumatic lower airway processes can be guided by the breath sounds, cardiac examination and the presence or absence of fever as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Wheezes",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       rales with fever",
"      </strong>",
"      &ndash; The presence of wheezes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rales with fever is consistent with infectious processes, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Pneumonia",
"      </strong>",
"      &ndash; Focal rales are typical findings in children with bacterial disease. Recognize that breath sounds are often transmitted throughout the chest of a small child which may mask focality. Diffuse rales",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      wheezing suggest viral or atypical pneumonia. The absence of these findings does not exclude the diagnosis of pneumonia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Clinical evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bronchiolitis",
"      </strong>",
"      &ndash; Bronchiolitis occurs primarily in infants less than two years of age. Typical clinical features include fever, nasal congestion, increased secretions, and retractions with diffuse wheezing and scattered rales. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16074?source=see_link&amp;anchor=H7#H7\">",
"       \"Bronchiolitis in infants and children: Clinical features and diagnosis\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Asthma with a febrile illness",
"      </strong>",
"      &ndash; A child with asthma who has fever and wheezing may have pneumonia. Respiratory tract infections that do not generally cause respiratory distress (ie, the common cold) may trigger an exacerbation in children with asthma. A chest radiograph to evaluate for pneumonia should be considered for patients with an asthma exacerbation and fever &ge;38.9&ordm;C (102&ordm;F), particularly when breath sounds remain consistently asymmetric despite treatment of bronchospasm. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link&amp;anchor=H2#H2\">",
"       \"Trigger control to enhance asthma management\", section on 'Respiratory infections'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link&amp;anchor=H6#H6\">",
"       \"Acute asthma exacerbations in children: Outpatient management\", section on 'Chest radiograph'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Myocarditis with heart failure",
"      </strong>",
"      &ndash; Children with viral myocarditis may have fever and be in respiratory distress from heart failure. Mild lower airway signs, such as tachypnea and rales, may be the only respiratory indications of heart involvement. Tachycardia with or without respiratory findings, particularly if unresponsive to fluids should increase level of suspicion for myocarditis. A new cardiac murmur or gallop may also be present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations and diagnosis of myocarditis in children\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Foreign body",
"      </strong>",
"      &ndash; Pneumonia may develop distal to a lower airway obstruction from an aspirated foreign body that may have been present for some time. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link&amp;anchor=H7#H7\">",
"       \"Airway foreign bodies in children\", section on 'Delayed diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Wheezes",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       rales without fever",
"      </strong>",
"      &ndash; Etiology of respiratory distress in afebrile children with wheezes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rales may be infectious or noninfectious, and while most commonly intrapulmonary, may be cardiac or mediastinal. Diagnoses include (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1689?source=see_link\">",
"       \"Wheezing illnesses other than asthma in children\"",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Atypical pneumonia",
"      </strong>",
"      &ndash; Children with atypical pneumonia, most commonly Mycoplasma pneumonia in school age children, and Chlamydia pneumonia, most commonly in infants born to infected mothers, often do not have fever but have rales or wheezes. Cough is also a predominant component of these diseases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=see_link&amp;anchor=H5#H5\">",
"       \"Mycoplasma pneumoniae infection in children\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33062?source=see_link&amp;anchor=H6#H6\">",
"       \"Pneumonia caused by Chlamydophila (Chlamydia) species in children\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Atelectasis",
"      </strong>",
"      &ndash; The physical findings of atelectasis in children tend to be minimal. In most cases, there are no changes in the physical exam although occasionally fever may be present. As an example, in the setting of asthma and compressive right middle lobe atelectasis, the upper and lower lobes will fill the space occupied by the collapsed lobe so that breath sounds can be normal in the right axilla. Crackles",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      wheezes may be heard over areas of obstructive atelectasis if the airway obstruction is incomplete and allows some airflow. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34903?source=see_link&amp;anchor=H7#H7\">",
"       \"Atelectasis in children\", section on 'Physical findings'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bronchiolitis",
"      </strong>",
"      &ndash; Some children with bronchiolitis may have wheezes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rales and be afebrile. Focal opacity on chest radiograph in afebrile patients with bronchiolitis may be due to atelectasis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16074?source=see_link&amp;anchor=H7#H7\">",
"       \"Bronchiolitis in infants and children: Clinical features and diagnosis\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Asthma",
"      </strong>",
"      &ndash; The most common cause of respiratory distress in afebrile children with wheezing is asthma. Children with severe symptoms should receive aggressive pharmacologic therapy, as well as evaluation for associated conditions, such as pneumothorax or pneumonia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link\">",
"       \"Acute asthma exacerbations in children: Outpatient management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Anaphylaxis",
"      </strong>",
"      &ndash; Anaphylaxis can cause bronchospasm, as well as upper airway obstruction. Exposure to a known trigger, facial edema, and an urticarial rash are also common features. Anaphylaxis induced bronchospasm typically responds well to treatment with epinephrine, bronchodilators, and steroids (",
"      <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"       \"Anaphylaxis: Rapid recognition and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pulmonary edema",
"      </strong>",
"      &ndash; Noncardiogenic pulmonary edema is a rare finding in children that may occur from a number of causes including upper airway obstruction, severe central nervous system insult, submersion injury, acute salicylate toxicity, and pulmonary irritants. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=see_link\">",
"       \"Noncardiogenic pulmonary edema\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Chronic pulmonary disease exacerbation",
"      </strong>",
"      &ndash; Children who are experiencing an exacerbation of a chronic pulmonary disease, such as cystic fibrosis, often have respiratory distress with abnormal breath sounds, such as wheezes or rales.",
"     </li>",
"     <li>",
"      <strong>",
"       Foreign body",
"      </strong>",
"      &ndash; Although breath sounds are typically asymmetric with foreign body aspiration into the lower airway, breath sounds may be symmetric because the foreign body is small",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      because breath sounds are transmitted across the chest of small children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link&amp;anchor=H4#H4\">",
"       \"Airway foreign bodies in children\", section on 'Signs and symptoms'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Heart failure",
"      </strong>",
"      &ndash; Children in respiratory distress from heart failure (HF) classically have rales on lung exam, as well as other signs of heart disease, such as abnormal heart sounds and organomegaly. Heart failure is often due to a congenital defect, some of which result in severe hypoxia and cyanosis while others present only with poor feeding and failure to thrive. Neonates with obstructive left heart lesions, such as severe coarctation of the aorta can develop severe HF when the ductus arteriosus closes. HF can also develop as the result of an arrhythmia, most commonly supraventricular tachycardia. In addition, children with myocarditis (from either an infectious or a noninfectious etiology, such as an autoimmune disorder) may have HF and be afebrile (",
"      <a class=\"graphic graphic_table graphicRef56995 \" href=\"UTD.htm?35/10/36014\">",
"       table 8",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20359?source=see_link&amp;anchor=H22#H22\">",
"       \"Cardiac causes of cyanosis in the newborn\", section on 'Heart failure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=see_link&amp;anchor=H12#H12\">",
"       \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\", section on 'Heart failure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=see_link\">",
"       \"Clinical manifestations and diagnosis of myocarditis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Mediastinal mass",
"      </strong>",
"      &ndash; An intrathoracic mass, such as a tumor, hemangioma, thymic mass, bronchogenic cyst, or enlarged lymph node, that compresses the airway can result in wheeze as well as cough. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=see_link&amp;anchor=H5#H5\">",
"       \"Evaluation of mediastinal masses\", section on 'Signs and symptoms'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Tachypnea with fever",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      For patients without wheeze or rales, tachypnea may be the only indicator of respiratory distress, particularly in those less than six months of age. The presence of fever suggests an infectious etiology within or outside the respiratory system, such as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Pneumonia",
"      </strong>",
"      &ndash; Breath sounds may be normal with lobar pneumonia or empyema, particularly in small children.",
"     </li>",
"     <li>",
"      <strong>",
"       Sepsis",
"      </strong>",
"      &ndash; Respiratory distress manifested as tachypnea may occur in patients with severe sepsis to compensate for metabolic acidosis. Respiratory status may be further compromised as the result of capillary leak in the lungs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link&amp;anchor=H13#H13\">",
"       \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pulmonary embolism",
"      </strong>",
"      &ndash; Fever has been reported as a nonspecific sign in patients with pulmonary embolism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of acute pulmonary embolism\", section on 'Symptoms / Signs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Encephalitis",
"      </strong>",
"      &ndash; Patients with encephalitis may have respiratory depression or tachypnea. Those with meningitis may have respiratory depression with or without signs of distress.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Tachypnea without fever",
"      </strong>",
"      &ndash; In patients with tachypnea without fever, noninfectious etiologies of the respiratory system as well as other systems most commonly cardiac or metabolic, should be suspected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Viral or mycoplasma pneumonia",
"      </strong>",
"      &ndash; Pneumonia due to viral pathogens or mycoplasma can present with tachypnea alone that is usually associated with cough. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Clues to etiology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=see_link&amp;anchor=H5#H5\">",
"       \"Mycoplasma pneumoniae infection in children\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pulmonary irritant",
"      </strong>",
"      &ndash; Inhaled biological or chemical agents can cause irritation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inflammation that results in tachypnea. Agents of biologic warfare, particularly nerve gases often impact children first because these gases are heavier than air, thus more concentrated at the level at which children breath, and because children breath more rapidly than adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8521?source=see_link&amp;anchor=H11#H11\">",
"       \"Chemical terrorism: Diagnosis and treatment of exposure to chemical weapons\", section on 'Pulmonary symptoms'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Intrapulmonary mass",
"      </strong>",
"      &ndash; Children with tumor, bronchogenic cyst, or congenital diaphragmatic hernia may present with isolated tachypnea as an initial or later finding.",
"     </li>",
"     <li>",
"      <strong>",
"       Spontaneous pneumothorax",
"      </strong>",
"      &ndash; Risk factors for spontaneous pneumothorax include tall thin body habitus, asthma, and high intrapulmonary pressure generated by smoking drugs, particularly marijuana. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40793?source=see_link&amp;anchor=H6#H6\">",
"       \"Spontaneous pneumothorax in children\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pulmonary embolism (PE)",
"      </strong>",
"      &ndash; A PE classically causes respiratory distress with chest pain. It is an uncommon condition in children that is often associated with the use of central venous lines or access devices. Other risk factors for PE include a hypercoagulable state (ie, factor V Leiden), congenital heart disease, trauma, nephrotic syndrome, lupus erythematosus, and complications of some chemotherapeutic regimens (ie, L-asparaginase and steroids for acute lymphoblastic leukemia). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25033?source=see_link&amp;anchor=H8#H8\">",
"       \"Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cardiac disease",
"      </strong>",
"      &ndash; Tachypnea with normal breath sounds and no fever may be a sign of cardiac disease. Cardiac conditions that cause heart failure include congenital lesions, myocarditis, and arrhythmias. Heart sounds may be normal or abnormal depending upon the underlying cardiac condition. Pericardial effusion or tamponade can also cause respiratory distress. Pain as the result of pericarditis may result in splinting with respiration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20359?source=see_link&amp;anchor=H22#H22\">",
"       \"Cardiac causes of cyanosis in the newborn\", section on 'Heart failure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=see_link\">",
"       \"Clinical manifestations and diagnosis of myocarditis in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=see_link&amp;anchor=H12#H12\">",
"       \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\", section on 'Heart failure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"       \"Cardiac tamponade\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Metabolic derangement",
"      </strong>",
"      &ndash; Tachypnea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an abnormal respiratory pattern may also occur as a response to metabolic acidosis (as in shock or diabetic ketoacidosis), CNS stimulation (as with hyperammonemia), abnormalities associated with hemoglobin (ie, severe anemia or methemoglobinemia), conditions that increase metabolic rate (ie, hyperthyroidism or fever), splinting from pain, or a thoracic mass or deformity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6330?source=see_link&amp;anchor=H15#H15\">",
"       \"Approach to the child with metabolic acidosis\", section on 'Clinical evaluation and diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=see_link&amp;anchor=H6#H6\">",
"       \"Urea cycle disorders: Clinical features and diagnosis\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory distress is characterized by increased work of breathing, resulting in signs that include tachypnea or hyperpnea, use of accessory muscles,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abnormal breath sounds. It is a common complaint among children seeking medical care.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with potentially life-threatening respiratory compromise must receive immediate treatment, often before a comprehensive evaluation can be completed (",
"      <a class=\"graphic graphic_table graphicRef57278 \" href=\"UTD.htm?2/46/2797\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef55990 \" href=\"UTD.htm?22/48/23296\">",
"       algorithm 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef51456 \" href=\"UTD.htm?17/26/17837\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Initial rapid assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes of respiratory distress include trauma, respiratory illnesses, such as pneumonia, asthma, bronchiolitis, or foreign body aspiration; cardiac disease, such as structural heart disease and myocarditis, with heart failure, and metabolic disturbances, such as acidosis (",
"      <a class=\"graphic graphic_table graphicRef61637 \" href=\"UTD.htm?27/39/28285\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39113?source=see_link\">",
"       \"Causes of acute respiratory compromise in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39113?source=see_link&amp;anchor=H13169095#H13169095\">",
"       \"Causes of acute respiratory compromise in children\", section on 'Causes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evaluation includes a rapid initial assessment to identify children who require immediate supportive care, followed by a more detailed history and physical examination. Ancillary studies should be performed as indicated (",
"      <a class=\"graphic graphic_table graphicRef82210 \" href=\"UTD.htm?39/25/40349\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The algorithm provides a diagnostic approach to the causes of acute respiratory distress in children caused by lower airway disease and based upon physical examination (",
"      <a class=\"graphic graphic_algorithm graphicRef66401 \" href=\"UTD.htm?39/24/40322\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Other respiratory distress'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7130/abstract/1\">",
"      Krauss BS, Harakal T, Fleisher GR. The spectrum and frequency of illness presenting to a pediatric emergency department. Pediatr Emerg Care 1991; 7:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7130/abstract/2\">",
"      Donoghue AJ, Nadkarni V, Berg RA, et al. Out-of-hospital pediatric cardiac arrest: an epidemiologic review and assessment of current knowledge. Ann Emerg Med 2005; 46:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7130/abstract/3\">",
"      Gerein RB, Osmond MH, Stiell IG, et al. What are the etiology and epidemiology of out-of-hospital pediatric cardiopulmonary arrest in Ontario, Canada? Acad Emerg Med 2006; 13:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7130/abstract/4\">",
"      Nadkarni VM, Larkin GL, Peberdy MA, et al. First documented rhythm and clinical outcome from in-hospital cardiac arrest among children and adults. JAMA 2006; 295:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7130/abstract/5\">",
"      McNally B, Robb R, Mehta M, et al. Out-of-hospital cardiac arrest surveillance --- Cardiac Arrest Registry to Enhance Survival (CARES), United States, October 1, 2005--December 31, 2010. MMWR Surveill Summ 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     Pediatric Advanced Life Support Provider Manual. Ralston, M, et al (Eds), American Heart Association, Subcommittee on Pediatric Resuscitation, Dallas, 2006, p.33.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7130/abstract/7\">",
"      O'Dempsey TJ, Laurence BE, McArdle TF, et al. The effect of temperature reduction on respiratory rate in febrile illnesses. Arch Dis Child 1993; 68:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7130/abstract/8\">",
"      Gadomski AM, Permutt T, Stanton B. Correcting respiratory rate for the presence of fever. J Clin Epidemiol 1994; 47:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7130/abstract/9\">",
"      Margolis P, Gadomski A. The rational clinical examination. Does this infant have pneumonia? JAMA 1998; 279:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/61/7130/abstract/10\">",
"      Poets CF, Southall DP. Noninvasive monitoring of oxygenation in infants and children: practical considerations and areas of concern. Pediatrics 1994; 93:737.",
"     </a>",
"    </li>",
"    <li>",
"     Dieckmann RA. Pediatric assessment. In: APLS: The Pediatric Emergency Medicine Resource, Gausche-Hill M, Fuchs S, Yamamoto L.  (Eds), Jones and Bartlett, Sudbury 2004. p.20.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6463 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B5D3664DDB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_61_7130=[""].join("\n");
var outline_f6_61_7130=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6610635\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Initial rapid assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - General observation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1164272\">",
"      - Vital signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3777178\">",
"      - Breathing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Other organ systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Bedside evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1164505\">",
"      - Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1165119\">",
"      Upper airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1165126\">",
"      Impending respiratory arrest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Other respiratory distress",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6450456\">",
"      - Trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6450480\">",
"      - No trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6463\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6463|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?39/24/40322\" title=\"algorithm 1\">",
"      Diagnostic approach to acute respiratory compromise in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/48/23296\" title=\"algorithm 2\">",
"      Complete airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?9/37/9810\" title=\"algorithm 3\">",
"      Severe upper airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6463|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/51/43834\" title=\"figure 1\">",
"      Initial trauma management in the severely injured child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6463|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/0/8197\" title=\"picture 1\">",
"      Epiglottitis classic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6463|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/39/28285\" title=\"table 1\">",
"      Causes acute respiratory distress in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/23/25980\" title=\"table 2\">",
"      Localization of pediatric respiratory distress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/25/40349\" title=\"table 3\">",
"      Diagnostic studies for pediatric respiratory distress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/46/2797\" title=\"table 4\">",
"      Management of life-threatening acute respiratory compromise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/37/28252\" title=\"table 5\">",
"      Normal respiratory rate and heart rate in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/26/17837\" title=\"table 6\">",
"      Rapid overview of rapid sequence intubation in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/50/18221\" title=\"table 7\">",
"      Rapid overview for pediatric anaphylaxis treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/10/36014\" title=\"table 8\">",
"      Causes of myocarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=related_link\">",
"      Acute asthma exacerbations in children: Outpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6330?source=related_link\">",
"      Approach to the child with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=related_link\">",
"      Approach to the child with occult toxic exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34903?source=related_link\">",
"      Atelectasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16074?source=related_link\">",
"      Bronchiolitis in infants and children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20359?source=related_link\">",
"      Cardiac causes of cyanosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39113?source=related_link\">",
"      Causes of acute respiratory compromise in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28088?source=related_link\">",
"      Causes of chronic cough in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8521?source=related_link\">",
"      Chemical terrorism: Diagnosis and treatment of exposure to chemical weapons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12807?source=related_link\">",
"      Chest wall injuries in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=related_link\">",
"      Clinical features and diagnosis of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=related_link\">",
"      Emergency pericardiocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=related_link\">",
"      Emergent evaluation of acute upper airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=related_link\">",
"      Evaluation of mediastinal masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28136?source=related_link\">",
"      Evaluation of stupor and coma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=related_link\">",
"      Initial approach to severe traumatic brain injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=related_link\">",
"      Initial assessment and stabilization of children with respiratory or circulatory compromise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=related_link\">",
"      Initial evaluation of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=related_link\">",
"      Methanol and ethylene glycol poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=related_link\">",
"      Mycoplasma pneumoniae infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=related_link\">",
"      Noncardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31511?source=related_link\">",
"      Overview of neonatal respiratory distress: Disorders of transition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25033?source=related_link\">",
"      Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33062?source=related_link\">",
"      Pneumonia caused by Chlamydophila (Chlamydia) species in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=related_link\">",
"      Pulse oximetry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40793?source=related_link\">",
"      Spontaneous pneumothorax in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=related_link\">",
"      Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=related_link\">",
"      Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=related_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=related_link\">",
"      Urea cycle disorders: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1689?source=related_link\">",
"      Wheezing illnesses other than asthma in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_61_7131="Causes of vulvovaginal pruritus";
var content_f6_61_7131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of vulvovaginal pruritus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Vaginitis (infectious or atrophic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atopic, contact, or seborrheic dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psoriasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lichen sclerosus, planus, or simplex chronicus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vulvar intraepithelial neoplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vulvar cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paget's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vulvar infection (bacterial, fungal, viral)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hidradenitis suppurativa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scabies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pediculosis pubis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic diseases with vulvar involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vulvodynia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_61_7131=[""].join("\n");
var outline_f6_61_7131=null;
var title_f6_61_7132="Poisoned patient ICU criteria";
var content_f6_61_7132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for ICU admission of poisoned patient",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        CNS depression, including significant lethargy, coma (Glasgow coma scale &le;6)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Agitation requiring chemical or physical restraint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory depression (PCO2 &gt;45 mmHg), hypoxia or respiratory failure (ARDS), and/or endotracheal intubation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotension (SBP &le;80 mmHg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Second or third degree AV block on ECG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonsinus cardiac rhythm on ECG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Significant acid-base disturbances (eg, metabolic acidosis with pH &le;7.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Significant metabolic abnormalities requiring close monitoring or aggressive correction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extremes of temperature (eg, hyperthermia with T &gt;104&deg;F)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Poisoning with a \"toxic time bomb\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ingested drug packets, sustained-release preparations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Quantitative level of drug which predicts unfavorable outcome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Need for invasive hemodynamic monitoring (eg, pulmonary artery catheter or arterial line) or cardiac pacing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Need for whole bowel irrigation to enhance GI elimination of poison",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Need for emergency hemodialysis, hemoperfusion, hemofiltration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Need for emergency antidote which requires close monitoring (eg, crotalid antivenin, Digibind, physostigmine, naloxone drip)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ischemic chest pain from toxin (eg, cocaine, carbon monoxide)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TCA or other drug exposure with QRS &gt;120 msec or QTc &gt;500 msec",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_61_7132=[""].join("\n");
var outline_f6_61_7132=null;
var title_f6_61_7133="TPA does not reduce cardiac events in unstable angina";
var content_f6_61_7133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thrombolysis does not reduce cardiac events in unstable angina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 245px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the TIMI IIIB trial, which randomized 1473 patients with unstable angina or a non-Q-wave myocardial infarction to thrombolytic therapy with tissue-type plasminogen activator (tPA) or placebo, there was no difference in the one year incidence of death or myocardial infarction between the two groups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Anderson HV, Cannon CP, Stone PH, et al. J Am Coll Cardiol 1995; 26:643.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_61_7133=[""].join("\n");
var outline_f6_61_7133=null;
var title_f6_61_7134="Fish intake and sudden death";
var content_f6_61_7134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    The consumption of fish and fish oil reduces the risk of sudden death",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 205px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Physicians' Health Study of 20,551 men without evidence of heart disease, followed for up to 11 years, found the risk of sudden cardiac was lower with modest intake of fish (1-2 servings per week) and less than 2 grams of long-chain n-3 fatty acid intake per month. More intake of fish or n-3 fatty acids above these modest levels was not associated with further risk reduction.",
"    <br>",
"     <br>",
"      The hatched area represent pointwise 95 percent confidence intervals for the relative hazard function.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Data from: Albert CM, Hennekens CH, O'Donnell CJ, et al. JAMA 1998; 279:23.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_61_7134=[""].join("\n");
var outline_f6_61_7134=null;
var title_f6_61_7135="US pertussis cases by age 2012";
var content_f6_61_7135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 576px\">",
"   <div class=\"ttl\">",
"    Incidence of confirmed and probable pertussis among persons aged &le;19 years, by patient age and vaccines received &mdash; National Notifiable Diseases Surveillance System, United States, January 1&ndash;June 14, 2012",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 556px; height: 398px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acellular vaccines (DTaP) replaced whole-cell vaccines (DTwP) for the 4",
"    <sup>",
"     th",
"    </sup>",
"    and 5",
"    <sup>",
"     th",
"    </sup>",
"    doses in 1992 and all five doses of the childhood series in 1997. Tdap was recommended for adolescents aged 11 to 12 years in 2006. Thus, all children aged &le;14 years are likely to have received acellular vaccines for the complete childhood series. Adolescents aged 15 years were born during a transition year from whole-cell to acellular vaccines for the childhood series. Adolescents aged &ge;16 years received whole-cell vaccines for the first three doses, and acellular vaccines for the 4",
"    <sup>",
"     th",
"    </sup>",
"    and 5",
"    <sup>",
"     th",
"    </sup>",
"    doses.",
"    <div class=\"footnotes\">",
"     DTaP: diphtheria and tetanus toxoids and acellular pertussis; DTwP: diphtheria and tetanus toxoids and whole-cell pertussis; Tdap: tetanus and reduced diphtheria toxoids and acellular pertussis.",
"     <br/>",
"     * Ages during which the Advisory Committee on Immunization Practices recommends that specified vaccine doses be administered.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Pertussis epidemic - Washington, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:517.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_61_7135=[""].join("\n");
var outline_f6_61_7135=null;
